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GENERAL INTRODUCTION
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a progressive disease defined by a not 
fully reversible airflow limitation.1 This airflow limitation is represented by a forced 
expiratory volume in 1s (FEV1)/forced vital capacity (FVC) <0.7 after bronchodilation.1 
The FEV/FVC ratio together with FEV1 as percentage of predicted is used to classify 
COPD severity according to the Global initiative for chronic Obstructive Lung Disease 
(GOLD) classification (for a detailed description see http://www.goldcopd.org; Table
1).1 This expiratory airflow limitation is caused by small airway obstruction via 
bronchial inflammation and mucus hypersecretion (chronic bronchitis) and by the 
loss of lung elastic recoil, increasing the lung compliance and collapsibility of small 
airways (emphysema). These causes of flow limitation are associated with an abnormal 
inflammatory response of the lungs to noxious particles or gases, mainly tobacco smoke. 
Next to lung involvement, COPD also includes significant systemic consequences.1
Table 1. Spirometric classification of COPD.
Stage Post-bronchodilator
FEV1/FVC
FEV1%pred
1: mild COPD <0.70 >80
II: moderate COPD <0.70 50-80
III: severe COPD <0.70 30-50
IV: very severe COPD <0.70 <30 or <50 plus chronic respiratory failure (Pa02 
<8.0kPa and/or PaC02 >6.7kPa)
COPD: chronic obstructive pulmonary disease, FEV1: forced expiratory volume in 1s, FVC: forced 
vital capacity, PaCO2: arterial carbon dioxide tension, PaO2: arterial oxygen tension.
Besides symptoms of cough and sputum production, dyspnea -the perception of 
respiratory discomfort- is the most common complaint in patients with COPD.1 The 
degree of dyspnea sensation is strongly related to the severity of exercise intolerance 
and to the reduction of health-related quality of life.2 Analogous to this major impact 
on individual patient level, COPD also has important consequences on population level, 
reflected by its worldwide increasing prevalence ranging from 8-26%3-6 and associated 
high healthcare costs.7 Furthermore, COPD is currently the fourth most common cause 
of death in the Western World and is expected to become third within ten years.89
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Operating lung volumes in COPD
Although a decrease in FEV1 is traditionally considered in the natural history of 
COPD,110 static hyperinflation is thought to develop simultaneously or even before a 
decline in FEV1.11-13 Static hyperinflation is defined as an increase in functional residual 
capacity (FRC), and occurs as a result of the expiratory airflow limitation in COPD. 
Figure 1 shows the different static lung volumes. FRC represents the equilibrium point 
between the opposing forces of the inward lung and the outward chest wall elastic 
recoil, which is reached after a normal exhalation. In contrast to the slow development 
of static hyperinflation over years, acute dynamic hyperinflation (DH) is the transient 
increase in FRC when ventilatory demand increases, e.g. during exercise.14
Figure 1. Lung volumes. ERV: expiratory reserve volume, FRC: functional residual capacity, IC: 
inspiratory capacity, IRV: inspiratory reserve volume, RV: residual volume, TLC: to ta l lung capacity, 
VC: vita l capacity, VT: tida l volume.
In this dynamic situation, FRC is called end-expiratory lung volume (EELV). Because of 
the expiratory flow limitation, COPD patients need more expiratory time to exhale 
the inspired tidal volume. However, during exercise COPD patients increase their 
ventilation mainly by increasing their breathing frequency, which reduces time for 
expiration.15 As a result, there is not enough time to exhale all the inspired air and 
DH occurs. The EELV increases as a consequence of DH, which aggravates the normal 
reduction of the inspiratory reserve volume (IRV) during exercise. Figure 2 represents 
operating lung volumes during exercise in a patient with COPD compared to a healthy 
subject.
The development of dyspnea upon exertion has a multidimensional nature16-18 and DH 
and decreased IRV are considered to be two important determinants.1920 Dyspnea is 
thought to originate from an imbalance between load and capacity of the respiratory 
muscles.17 In COPD patients, the load on the respiratory muscles during exercise is 
substantially higher than in normal subjects.21 This disproportional increase is caused
RV
Time
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by several mechanisms. First, DH leads to intrinsic positive end-expiratory pressure 
(alveolar pressure remains positive throughout expiration), which increases the 
threshold load for inspiration.17 Second, stiffness of the lung increases at higher lung 
volumes (i.e. DH) and breathing frequencies,22 increasing the elastic and flow-resistive 
work of breathing.23 Finally, enhanced load on the respiratory muscles is a normal 
response to exercise, since the ventilatory demand rises. Yet, in COPD the ventilatory 
demand in COPD patients is exaggerated by hypoxia, hypercapnia and lactatemia.17 
These are common phenomena in COPD, because of gas exchange abnormalities, 
ventilatory limitations, and muscle deconditioning.15
Figure 2. Course o f  lung volumes during incremental exercise in a COPD pa tien t and a healthy  
subject.
Next to a disturbed load of the respiratory muscles in COPD, their capacity is also 
affected. Lung hyperinflation, either dynamic or static, shortens the diaphragm. 
Considering the characteristic length-tension relationship of striated muscle, passive 
shortening of the diaphragm reduces its force generating capacity.17 Furthermore, 
studies on diaphragm muscle fibers from COPD patients demonstrate that intrinsic 
muscle abnormalities contribute to reduced force generating capacity.24 So the capacity 
of the respiratory muscles in COPD patients can hardly meet the increased load 
imposed on them during exercise. Consequently, the neural drive of the respiratory 
muscles increases excessively, without being accompanied by a proportional increase 
of ventilation.25 This results in a mismatch between efferent neural drive and afferent 
feedback to the respiratory center, which is referred to as neuromechanical dissociation 
and leads to the perception of dyspnea.17,26 A decrease in IRV to less than 0.5L, caused
9
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by (static and) dynamic hyperinflation, strongly associates with the occurrence of 
neuromechanical dissociation.26 Therefore, a change in IRV is a very good predictor 
of dyspnea during exercise.14 Thus, operating lung volumes, like DH and IRV, are very 
important determinants of complaints and limitations of COPD patients. Moreover, 
DH and its consequences correlate even better with patient-centered outcomes than 
FEV1.11 Although more and more attention is being paid to operating lung volumes 
during functional tests in patients with COPD, it is currently unknown whether DH 
develops during different daily activities of COPD patients. Furthermore, it is not 
clear whether DH occurs at different GOLD stages during these activities. Finally, the 
development of DH during the progression of COPD has never been studied.
Procedure o f measuring operating lung volumes
Determination of EELV is only possible by using inert gas dilution techniques or 
plethysmographic (body box) measurements. These methods require a certain amount 
of time for dilution and warming-up, respectively. However, EELV during exercise must 
be measured instantaneously. Furthermore, to determine DH via the plethysmographic 
method, exercise must be performed in the body box, which is impractical and requires 
an adapted device. Therefore, to determine DH, repeated inspiratory capacity (IC) 
measurements are usually performed at rest and repeatedly during exercise.14 IC is 
the maximal amount of air that can be inspired after a normal expiration (FRC or EELV 
level; Figure 1). IC can be easily measured during exercise with a simple flow meter, 
which converts the flow signal to a volume signal and which is also used for measuring 
other ventilatory parameters, as tidal volume, breathing frequency, and inspiratory 
and expiratory flow and time. Assuming that total lung capacity remains stable during 
exercise,27,28 changes in IC are equal but opposite to changes in EELV (Figure 1).
The IC maneuver requires a trained technician for adequate timing of the command 
and encouragement of the patient, and for analysis of the result. After at least four 
consistent EELV levels, subjects are instructed and stimulated to maximally inspire 
(to total lung capacity) and reach a volume plateau and then to return to normal 
breathing. Performance of the IC maneuver can be monitored by the real-time 
display of breathing volumes and observation of the subject. Prior to testing, three 
reproducible flow-volume curves29 are obtained. For analysis, the IC maneuver together 
with the preceding breaths is placed within the maximal flow-volume curve (Figure 3). 
Any inconsistency in the last breath preceding the IC maneuver is manually corrected 
to obtain a true EELV.30 IRV is calculated by subtracting tidal volume from IC. A 30s 
mean tidal volume preceding the IC maneuver is used to prevent the possible influence 
of IC performance on subsequent tidal volume.
10
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Figure 3. Example o f  a maximal expiratory flow-volume curve w ith  IC maneuver and preceding 
breathing loops o f  a COPD pa tien t a t rest (A) and during exercise (B). TLC: to ta l lung capacity.
Systemic effects in COPD
As mentioned, COPD is a systemic disease involving more than airflow limitation alone. 
For example, weight loss, muscle wasting and dysfunction, cardiovascular disease, 
osteoporosis, depression, cancer and, diabetes31-35 are several systemic manifestations 
that may occur in COPD. Increasing evidence indicates that these systemic effects are 
related to the presence of low-grade systemic inflammation.31,32,36 
Next to the low-grade systemic inflammation at rest, it has been shown that patients 
with COPD show an increased systemic response, including inflammation and 
oxidative stress, to maximal and submaximal exercise.3738 Attempts have been made 
to blunt these responses, by for example allopurinol (an 'anti-oxidant'), oxygen
11
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and rehabilitation.39'41 Although these interventions had a significant effect on the 
oxidative stress response, the effect on systemic inflammatory mediators was far 
less investigated. Besides, the effect on systemic inflammatory and oxidative stress 
responses to exercise of other interventions that aim to improve exercise tolerance, 
like non-invasive ventilation (NIV) and Heliox, have not been subject of research yet. 
Because suppression of systemic inflammation is expected to have positive effects 
on morbidity and mortality, a developing area of research is to study the effects of 
new potential anti-inflammatory drugs in COPD.32 For example, statins are recently 
suggested to have anti-inflammatory qualities,42 next to their well documented 
cholesterol-lowering properties.43,44 Besides suppressing inflammation, statin use in 
COPD may also be beneficial to treat cardiovascular disease as a comorbidity.
Indeed, cardiovascular disease is one important systemic effect observed in patients with 
COPD. Since there is a lack of longitudinal data, the pathophysiological mechanisms 
behind the coexistence of cardiovascular disease and COPD are poorly understood. A 
potential role has been attributed to systemic inflammation and physical inactivity. 
However, as systemic inflammation and physical inactivity are related45-47 and occur 
in both diseases,364849 no simple cause and effect can be pointed out. Cardiovascular 
disease is a major cause of heart failure (HF).50 Accordingly, COPD and HF have been 
shown to coincide frequently.51 However, combined prevalence is difficult to determine, 
because of overlapping risk factors, symptoms and signs; and concurrent disease may 
complicate additional diagnostics. Furthermore, data are often derived from databases 
and not from diagnoses according to the definitions. Therefore, studies concerning the 
prevalence of concurrent COPD and HF should be reviewed carefully in order to get a 
clearer view on this topic.
Structure of this thesis
This thesis addresses operating lung volumes and systemic effects as two important 
aspects of COPD. The studies described in this thesis are divided in two parts. The aim 
of the first part of the thesis was to investigate operating lung volumes in patients 
with varying degrees of COPD during different kinds of activities and during the 
progression of COPD. The main aim of the second part of the thesis was to investigate 
and review the effect of different interventions on systemic inflammatory responses 
in COPD. In addition, a critical review on the prevalence of simultaneous COPD and HF 
was performed.
In chapter 2, we investigated the repeatability and validity of Oxycon Mobile (OM) 
in measuring IC. OM is a mobile and wireless cardiopulmonary exercise testing device. 
Since OM is light-weighted and easy to transfer, it allows the measurement of operating 
lung volumes beyond laboratory situations. Therefore, OM was used to measure IC's
12
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and thus DH during real-life daily activities in chapter 3. Patients with COPD GOLD 
stage II, III and IV were visited at home and IC's were measured during self-chosen and 
self-paced dyspnea-causing daily activities. Daily activities are, for an important part, 
performed by the arms, and patients with COPD report more dyspnea during arm than 
during leg exercise.52 Since DH is a contributor to dyspnea,20 the effects of arm and leg 
exercise on DH were examined in chapter 4.
The determination of exercise-induced DH is time-consuming. Therefore, other 
methods to establish DH have been sought. The metronome-paced hyperventilation 
(MPH) test has been shown to produce comparable results with regard to DH as 
incremental cycling induced DH.53 Similar to exercise, ventilatory requirements are 
increased during MPH. No data are available about the progression of DH, in contrast 
to the decline in FEV1 over time.10 Therefore, in chapter 5, we investigated DH after 
MPH in COPD during two years of follow-up.
COPD is associated with a low-grade systemic inflammation,36 and (low levels of) exercise 
induce a systemic inflammatory response, especially in muscle-wasted patients.37,38 In 
an attempt to blunt this inflammatory response, in chapter 6, we investigated the 
effect of non-invasive ventilation on exercise-induced inflammation in muscle-wasted 
patients with COPD.
Besides the cholesterol-lowering properties of statins, anti-inflammatory effects have 
recently been observed.42 In chapter 7, we reviewed the preliminary positive effects of 
statins in COPD and discussed possible mechanisms. Statins are abundantly being used 
in cardiovascular disease.43 44
Cardiovascular disease is regarded as a systemic effect of COPD32 and an important 
cause of HF.50 Because combined COPD and HF may be difficult to determine precisely, 
chapter 8 reviews studies concerning the prevalence of concomitant COPD and HF 
with specific attention for difficulties in diagnosis making, and limitations of the 
available data.
Finally, chapter 9 summarizes the most important findings of this thesis and discusses 
implications of the conclusions and future perspectives.
13
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VALIDITY OF OXYCON MOBILE IN MEASURING INSPIRATORY 
CAPACITY IN HEALTHY SUBJECTS
Clin Physiol Funct Imaging 2010;30:206-209.
ABSTRACT
Introduction Inspiratory capacity (IC) assessments have been performed mainly in 
laboratory settings, because of fixed measurement devices. Oxycon Mobile (OM) is the 
mobile and wireless version of Oxycon Pro (OP), a commonly used fixed measurement 
device. The purpose of this study was to examine IC agreement between OM and OP 
at rest and during steady-state exercise. Also, the within- and between-days variability 
of IC's were determined.
Methods Thirty-five healthy subjects were recruited. Twenty-five subjects were 
included for determining validity of the OM and ten subjects for the variability study. 
For validation of OM, resting and exercise IC's (ICrest and ICexercise respectively) were 
measured consecutively by OM and OP, in random order. Exercise consisted of cycle 
ergometry at 50% of subject's predicted maximal exercise capacity.
Results The mean difference between OM and OP regarding ICrest was -0.05L, with limits 
of agreement of -0.47 to 0.37L (or -1.2% with limits of agreement of -11.6 to 9.3%) (p>0.05). 
The mean difference of ICexercise was -0.06L and the limits of agreement were -0.48 
to 0.35L (or -1.4% with limits of agreement of -11.8 to 9.0%) (p>0.05). No significant 
differences in IC's within- or between-days were found.
Conclusions The limits of agreement of the IC measured by OM and OP were ±10%, 
which is recommended for interdevice reproducibility. We conclude that OM and OP 
can be used interchangeably for measuring IC at rest and during steady-state exercise.
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Repeated inspiratory capacity (IC) measurements are commonly used to assess changes 
in lung volumes during exercise in patients with chronic obstructive pulmonary disease 
(COPD). Lung volumes are susceptible to change during activity and in patients with 
COPD these changes contribute to sensations of breathlessness.12 In studies investigating 
activity-related breathlessness, a quantitative assessment of lung volumes is therefore 
of great importance and benefit.
IC assessments have been performed mainly in laboratory settings, because of fixed 
measurement devices. Oxycon Mobile (OM) is the mobile and wireless version of Oxycon 
Pro (OP), a commonly used fixed measurement device. Oxycon is a cardiopulmonary 
exercise testing system and allows measurement of, among other parameters, IC. 
To measure and calculate inspiratory and expiratory flow and volume, Oxycon has a 
turbine volume transducer, which is one of the four methods recommended by the 
American Thoracic Society (ATS).3 The advantage of OM is that it is light weighted, 
easy to transfer and therefore has the possibility to measure beyond laboratory 
situations. It is unclear whether OM and OP can be used interchangeably regarding IC 
measurements.
The purpose of this study was to examine IC agreement between OM and OP at 
rest and during steady-state exercise. Also, the accuracy of OM and the within- and 
between-days variability of IC's were determined. As patients with COPD, inherent to 
the disease, have a larger variability in IC, validity and variability of the OM was tested 
in healthy subjects.
METHODS
Subjects
Thirty-five healthy subjects were recruited. Twenty-five subjects were included for 
determining validity of the OM in measuring IC (group A) and 10 subjects for the 
variability study of IC (group B). Exclusion criteria were a history of asthma or COPD or 
abnormal pulmonary function. The study was conducted according to the Declaration 
of Helsinki and was approved by the medical ethical committee of our hospital. All 
subjects gave their written informed consent.
Study design
For validation of OM, resting and exercise IC's (ICrest and ICexercise respectively) were 
measured consecutively by OM and OP, in random order. Exercise consisted of cycle 
ergometry at 50% of subject's predicted maximal exercise capacity.4 
At rest and during steady-state exercise IC maneuvers were performed three times in 
succession according to the ATS guidelines.5 To avoid influence of the preceding IC,
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1min was kept between each maneuver. The mean values of the three maneuvers were 
used to determine validity, also in compliance with these guidelines.5 End-expiratory 
lung volume in healthy subjects was assumed to remain constant after reaching steady- 
state exercise. Repeatability of each method limits the amount of possible agreement,6 
and IC repeatability (three consecutive IC's) was therefore assessed for OM and OP. 
Accuracy of the OM was determined by using a calibration syringe with a fixed volume 
of 3L. This syringe was filled and emptied ten times, with strokes ranging from <1 to 15s 
to simulate high and low flow rates.3 To assess within- and between-days variability, IC's 
were measured at three different time points, at rest and during exercise (both three 
consecutive times; the mean was taken for analysis) using OM. The first and second 
time points were on the first day, in the morning and in the afternoon (within-day 
variability) respectively, and the third time point was on another day in the morning. 
The first and third time points were compared for between-days variability.
Pulmonary function (Masterlab, Viasys Healthcare, Hoechberg, Germany) and body 
height and weight were assessed as part of the characterization procedure.
Oxycon Mobile & Oxycon Pro
OM and OP (Viasys Healthcare, Hoechberg, Germany) consist of a face mask with 
turbine and integrated O2 and CO2 electrodes and a pulse oxymeter. Before each test, 
after 15min acclimatization, temperature, humidity and barometric pressure were 
determined and 2-point calibrations of turbine and gas analyzers were performed. 
Both systems fulfil the ATS criteria.3 OM is a telemetric system and consists of a 
measuring and transmitting unit and a fixed receiving unit. The measuring and 
transmitting units were attached to the subjects' back with a harness (total weight 
950g). The transmitting unit must be within a range of 500m of the receiving unit. All 
measurements were performed by a trained investigator.
Inspiratory capacity maneuver
Prior to testing, three reproducible flow-volume curves were obtained. The highest 
values for forced expiratory volume in 1s (FEV1) and forced vital capacity (FVC) were 
selected.5 For analysis, the IC maneuver, together with the preceding breaths was 
placed within the maximal flow-volume curve (Figure 1). Any inconsistency in the 
last breath preceding the IC maneuver was manually corrected to obtain a true end- 
expiratory lung volume.7 Performance of the IC maneuver was monitored by the real­
time display of breathing volumes. After at least four consistent end-expiratory lung 
volume levels, subjects were instructed and encouraged to maximally inspire (to total 
lung capacity) and reach a volume plateau and then to return to normal breathing.
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Statistics
Agreement between the OM and OP was displayed using the limits of agreements 
method of Bland and Altman.6 It is appropriate to average all the observations when the 
usual clinical measurement is the average of that number of observations.8 Therefore, 
mean IC's were taken to compare OM and OP.5 We considered limits of agreement 
of 10% of the (average) IC's to be acceptable.5 For repeatability, the within-subject 
coefficients of variation (CV's) of ICrest and ICexercise were calculated and averaged 
for OM and OP. CV is calculated by (SD/mean)x100%. CV's were also used to assess 
accuracy. Variability was reflected by the CV and by the coefficient of repeatability 
(CR). CR is calculated by SD of the difference%2, reflecting the maximum difference 
which is likely to occur between two measurements.
All values are expressed as mean ± SD. Differences between IC measurements by OM 
and OP and within- and between-days differences were tested using paired t-tests. 
Statistical significance was set at the p<0.05 level. Data were analyzed with SPSS, 
version 16.0 (SPSS, Chicago, IL).
Maximal flow-volume curve
Figure 1. Example o f  a maximal expiratory flow-volume curve w ith  IC maneuver and preceding 
resting breathing loops. The volume expired during the firs t second o f  the maximal expiratory 
flow-volume maneuver is the forced expiratory volume in 1s, and the to ta l expired volume is the 
forced vital capacity. The area above the x-axis (volume) is expiration, and the area under the 
x-axis is inspiration. The area rig h t from  the vertical line is the end-expiratory lung volume. IC: 
inspiratory capacity, TLC: to ta l lung capacity.
RESULTS
Subject characteristics
The study groups consisted of both men and women. Age ranged from 19 to 53 years 
and from 20 to 62 years for group A and group B respectively. All participants had 
normal lung function (Table 1).
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Table 1. Subject characteristics.
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Group A Group B
N 25 10
Gender (M/F) 11/25 4/6
Age (yrs) 33 ± 12 39 ± 15
BMI (kg/m2) 25.4 ± 5.8 26.3 ±6.6
50%Wmax pred (W) 108 ± 36 106 ±32
FEV1 (L) 4.10 ± 1.01 3.77 ± 0.86
FEV1 (%pred) 109 ± 14 108 ± 16
FEV1/FVC (% ) 79 ±0 78 ±8
TLC (L) 6.75 ± 1.31 6.46 ± 0.78
TLC (%pred) 108 ± 10 106 ±8
Data are presented as mean ± SD. BMI: body mass index, FEV1: forced expiratory volume in 1s, FVC: 
forced vital capacity, TLC: total lung capacity, Wmax pred: predicted maximal exercise capacity.
Validity
Mean ICrest measured by OM was 3.40 ± 0.90L and by OP 3.51 ± 0.90L (p>0.05). Within- 
subject CV's were 3.4 and 3.5% respectively. The mean difference between OM and OP 
regarding ICrest was -0.05 ± 0.22L, with limits of agreement of -0.47 to 0.37L. Figure 2 
shows the relative difference (with limits of agreement) of ICrest between both devices.
Figure 2. Bland & A ltm an m ethod p lo tting  the difference in ICrest measured by OM and OP. 
The mean difference is the cutting p o in t o f  the y- and x-axis, and the lim its o f  agreement are 
displayed by dashed lines. IC: inspiratory capacity, OM: Oxycon Mobile, OP: Oxycon Pro.
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ICexercise measured by OM was 3.66 ± 0.84L and by OP 3.70 ± 0.91L (p>0.05). Within- 
subject CV's were 2.7 and 2.8% respectively. The mean difference of ICexercise was 
-0.06 ± 0.21L, and the limits of agreement were -0.48 to 0.35L. Figure 3 shows the 
relative bias and limits of agreement of ICexercise.
___________________________________________  9.0%
• •
*  •
-------1--------- 1— * i * ! *  |— - — |-------- a--------- 1 -1.4 ± 5 .3%
1 2 «• • *  .  5 6 7 
• •
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Figure 3. Bland & A ltm an m ethod p lo tting  the difference in ICexercise measured by OM and  
OP. The mean difference is the cutting p o in t o f the y- and x-axis, and the lim its o f  agreement are 
displayed by dashed lines. Ex: exercise, IC: inspiratory capacity, OM: Oxycon Mobile, OP: Oxycon 
Pro.
As flow-volume curves were performed prior to IC testing, validity of OM in measuring 
FEV1 and FVC could also be examined. The mean relative difference between OM and 
OP for FEV1 was -1.2 ± 2.7% (limits of agreement -6.5% to 4.1%; p>0.05) and for FVC 
-1.9 ± 2.4% (limits of agreement -6.7% to 2.9%; p>0.05).
Accuracy and variability
Measured volume by OM with the 3L calibration syringe was 2.98 ± 0.01L, and the CV 
of the ten repetitions was 0.4%.
Mean ICrest at time point one, two and three were 3.51 ± 0.76L, 3.67 ± 0.69L and 3.58 
± 0.65L respectively. Within-days variability expressed as CV was 5.2% and expressed as 
CR 0.50L (p>0.05). The CV for ICrest between days was 5.5% and the CR 0.59L (p>0.05). 
ICexercise was 3.54 ± 0.67L, 3.59 ± 0.65L and 3.54 ± 0.61L for time points one, two and 
three respectively. The CV for within-day variability was 2.1% and for between days 
variability 3.7%, the CR's were 0.24 and 0.51L respectively (both p>0.05).
DISCUSSION
In this study we found that the bias between OM and OP in measuring IC was only 
-0.05L or -1.2% during rest and -0.06L or -1.4% during steady-state exercise. The limits 
of agreement of ICrest were ±10%, which is recommended by the ATS for interdevice
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reproducibility.5 No single subject exceeded the 10% limit. The limits of agreement 
of ICexercise were comparably small, with almost all measurements within the 10% 
range. We conclude that OM and OP can be used interchangeably for measuring IC at 
rest and during steady-state exercise in healthy subjects.
The CV's of within-subject variability of consecutive IC's (repeatability) were 
approximately 3% for both devices. The mean value of the three consecutive maneuvers 
must be reported for IC, instead of the largest value for FEV1 and FVC.5 Furthermore, 
in contrast to these measurements, no maximum difference between the three 
obtained IC values is recommended.5 Nevertheless, we found good repeatability of IC. 
Assuming constant total lung capacity at rest and during exercise, change in IC is used 
to assess change in end-expiratory lung volume (dynamic hyperinflation) in patients 
with COPD.910 In patients with chronic airflow obstruction, the CV for repeatability of 
resting IC has been found to be 5%.11 As this is comparable to the value we found in 
healthy subjects, we assume that our validity results can be extrapolated to patients 
with COPD.
The ATS guideline recommends an accuracy of 3% of flow or volume transducers5 and 
according to the manufacturer both OM and OP have an accuracy of 2%. We found 
an even better accuracy of OM of 0.4%. Variability of IC within- and between-days 
was small, reflecting good reproducibility of OM regarding IC measurements. Besides 
random measurements errors, also biological fluctuation, subject motivation and 
learning effects could play a role. In the case of COPD, potentially larger fluctuations 
in airway function and differences in medication use12 could be additional sources of 
variation within- and between-days. However, test-retest reproducibility (between 
days) of IC in patients with COPD was investigated and was found to be good.13 
In contrast to IC measurements, OM and OP employ different methods to assess oxygen 
uptake and carbon dioxide release, which might increase the difference between the 
two devices in measuring these parameters. Earlier, OP was validated against the 
Douglas bag method regarding gas exchange, and good agreement was reported for 
oxygen uptake and carbon dioxide release in the physiological range.1415 Until now, 
like OP, validation of OM has only been performed for gas exchange parameters.16 
During incremental exercise testing, OM measured significantly lower oxygen uptake 
than OP at the highest work rates (>200W); however, at lower work rates and also 
during constant work rate exercise testing, no differences were found.16 Patients with 
COPD generally do not reach these high work rates and therefore these devices might 
be exchanged in the COPD activity testing setting for gas exchange parameters as well. 
In conclusion, agreement between OM and OP regarding IC measurements at rest 
and during steady-state exercise is good and therefore these two devices can be used 
interchangeably.
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DYNAMIC HYPERINFLATION DURING DAILY ACTIVITIES: DOES 
COPD GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG 
DISEASE STAGE MATTER?
Chest 2010;137:1116-1121.
ABSTRACT
Introduction One of the contributors to exercise limitation in COPD is dynamic 
hyperinflation (DH). Although DH appears to occur during several exercise protocols 
in COPD and seems to increase with increasing disease severity, it is unknown whether 
dynamic hyperinflation occurs at different severity stages according to the Global 
initiative for chronic Obstructive Lung Disease (GOLD) in daily life. The present study, 
therefore, aimed to compare DH between COPD GOLD stages II-IV during daily 
activities.
Methods Thirty-two clinically stable patients with COPD GOLD II (n=10), III (n=12), and 
IV (n=10) participated in this study. Respiratory physiology during a daily activity was 
measured at patients' homes with Oxycon Mobile. Inspiratory capacity maneuvers were 
performed at rest, at 2min intervals during the activity, and at the end of the activity. 
Assuming that total lung capacity remains stable, change in inspiratory capacity (AIC) is 
commonly used to reflect change in end-expiratory lung volume (similar but opposite) 
and therefore DH. The combination of static and dynamic hyperinflation was reflected 
by inspiratory reserve volume (IRV) during the activity.
Results Overall, decrease in IC occurred in GOLD II-IV without significant difference 
between the groups. There was a tendency for a smaller AIC in GOLD IV. DH was 
inversely related to static hyperinflation. IRV during the daily activity was related to 
the level of airflow obstruction.
Conclusions DH occurs independent of GOLD stage during real-life daily activities. The 
combination of static and dynamic hyperinflation, however, increases with increasing 
airflow obstruction.
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Chronic obstructive pulmonary disease (COPD) is a disease with major impact on 
patients' daily activities and sense of well-being, which is reflected by decreased 
health-related quality of life.1 Limitation in everyday activities is reported by patients 
with COPD and confirmed by objectively measured less physical activity.23 
Although no doubt exists about the decreased physical activity in patients with COPD, 
the origin of the limitation is less clear and mostly studied in laboratory settings. 
One of the contributors to exercise limitation is dynamic hyperinflation (DH).4 DH is 
a consequence of expiratory airflow limitation and occurs when ventilatory demand 
increases, leaving less time for expiration. The consequent increase in end-expiratory 
lung volume (EELV) and decrease in inspiratory reserve volume (IRV) result in dyspnea.56 
DH occurs not only during maximal and submaximal cycle tests4,7 but also during 6min 
walk tests in patients with COPD.89 Also, after arm exercise, DH has been shown in subjects 
with COPD.10 Very recently, our group found that in patients with COPD DH occurred 
during activities of daily living (ADL).11 Thus, DH seems to play a role in everyday life in 
patients with COPD. Furthermore, DH after a symptom-limited incremental cycle test 
was shown to be the best predictor of decreased physical activity,12 which supports the 
importance of this phenomenon.
One study found that DH increased with increasing Global initiative for chronic 
Obstructive Lung Disease (GOLD) stage,13 suggesting that the severity of flow limitation 
is mostly responsible for the amount of DH. O'Donnell and Webb argued, however, 
from two studies including >400 patients, that DH was absent in patients with severe 
resting hyperinflation.14 Following this reasoning, DH might be less in the patients with 
the most severe COPD.
In the present study, DH during daily life activities is compared between patients with 
COPD GOLD stages II-IV. We hypothesized that DH increases with increasing airflow 
obstruction, but that this flow limitation effect is blunted by a volume limitation in the 
patients with the most severe COPD.
METHODS
Subjects
Thirty-two clinically stable patients with COPD, GOLD stage II (n=10), III (n=12), and IV 
(n=10), participated in this study. Patients were recruited from our outpatient clinic. 
Exclusion criteria were long-term oxygen therapy, respiratory insufficiency, asthma, 
exercise-limiting comorbidity, or an exacerbation within 4 weeks before the study. The 
study was conducted according to the Declaration of Helsinki and was approved by 
the medical ethical committee of our hospital. Written informed consent was obtained 
from all participants.
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Study design
Respiratory physiology during an ADL was measured at patients' homes with an 
Oxycon Mobile (Viasys Healthcare, Hoechberg, Germany). Subjects were requested to 
do a personally chosen daily activity that usually gives the most dyspnea. They were 
asked to perform this activity in their common way until they would normally stop 
because of shortness of breath, with a maximum of 10min. The reproducibility of ADLs 
regarding DH was tested in 8 patients with COPD on two successive days. Mean DH 
was respectively 0.69 ± 0.13L and 0.68 ± 0.14L (p=0.73) for the same ADL on the two 
different days.
Patients scored their breathlessness on a 10-point Borg scale at rest and after their 
ADL.15 The modified Medical Research Council dyspnea scale (MMRC)1617 and 24h 
Clinical COPD Questionnaire (CCQ)18 were filled out by patients before the test. MMRC 
grades disability on a scale from 0 to 4 (increasing disability) and CCQ grades 3 domains: 
symptoms, functional state, and mental state (scale: 0 = best, 6 = worst). Pulmonary 
function and body height and weight were assessed during a visit to our clinic.
Oxycon Mobile
Respiratory physiology was measured using Oxycon Mobile, a telemetric breath-by- 
breath system. The Oxycon Mobile consisted of a face mask with turbine and integrated
O2 and CO2 electrodes, polar belt, pulse oxymeter, a measuring and transmitting 
unit, and a fixed receiving unit. The measuring and transmitting units and the face 
mask with turbine were attached to the patient's back with a harness (total weight 
950g). A windshield was used to avoid flow created by the patient's simply moving. 
The receiving unit was connected to a personal computer within a range of 500m 
of the patient. Before each test (after 15min acclimatization) temperature, humidity, 
and barometric pressure were determined and 2-point calibrations of turbine and gas 
analyzers were performed.
Before starting their ADL, patients were measured at rest for at least 2min until 
reaching a steady-state. Minute ventilation, tidal volume, oxygen consumption, and 
carbon dioxide production were measured breath-by-breath, whereas heart rate and 
oxygen saturation were measured continuously. Breathing reserve was calculated 
as the difference between estimated maximal ventilatory capacity (37.5xFEV1) and 
measured minute ventilation. The Oxycon Mobile has been validated previously.1920 All 
measurements were performed by a trained investigator.
Inspiratory capacity measurements using Oxycon Mobile
Prior to the test, three reproducible flow-volume curves were obtained. Inspiratory 
capacity (IC) maneuvers were performed at rest (ICrest), at 2min intervals during ADL, 
and at the end of the activity (peak). IC maneuvers were performed in the upright 
position to avoid influence of body position on TLC and, therefore, IC. After at least four
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consistent EELV levels, subjects were instructed and encouraged to maximally inspire 
and reach a volume plateau and then to return to normal breathing. A 30s mean tidal 
volume preceding the IC maneuver was taken to prevent the possible influence of IC 
performance on subsequent tidal volume. Assuming that TLC remains constant during 
exercise,2122 change in IC (AIC) is commonly used to reflect change in EELV (similar but 
opposite) and therefore DH.5 IRV was calculated as the difference between IC and tidal 
volume. Hyperinflation and its consequences might be better expressed using the IC/ 
TLC ratio23'25 instead of the absolute value of IC or EELV. Therefore, the ICrest/TLC ratio 
was calculated.
To ascertain that patients consistently inspired to a constant peak lung volume during 
ADL,23 we measured the stability of peak esophageal pressure at peak inspired 
volume plateau in seven patients in our laboratory. A compliance catheter (Microtek 
Medical BV, Zutphen, The Netherlands) was passed transnasally and positioned in 
the midesophagus. This catheter was kept in situ during the activity. IC maneuvers 
with volume (Pulmonet III, Sensormedics, Bilthoven, The Netherlands) and pressure 
(Validyne, Northridge, CA) recording were performed before and immediately after 
the ADL. With decreasing IC during ADL, oesophageal pressure immediately after ADL 
showed no difference compared with resting values (23.8 ± 3.1cmH2O versus 21.9 ± 
3.5cmH2O, p=0.40). Further, we measured IC and TLC by the helium-dilution method 
before and immediately after ADL. IC significantly decreased (p<0.05), whereas TLC did 
not change with ADL (6.42 ± 1.39 versus 6.60 ± 1.50L, p=0.07).
Statistics
Data are presented as mean ± SE. ADL parameters are presented as mean values of the 
last minute of ADL. Baseline and ADL values between different GOLD categories were 
compared using analysis of variance and post hoc comparisons (Bonferroni). In case of 
unequal variances (FEV1 (%pred) and oxygen uptake (VO2)), Kruskal-Wallis with Dunn 
multiple comparison tests were performed. Pearson correlation coefficient was used to 
establish correlations between resting and ADL parameters. A p<0.05 level of statistical 
significance was used. Data were analyzed with SPSS, version 16.0 (SPSS, Chicago, IL).
RESULTS
Subjects
Age, gender and body mass index were comparable across the GOLD groups (Table 1). 
Smoking history was similar between the groups (II: 38 ± 9, III: 34 ± 5, and IV: 32 ± 5 
pack years). All but three patients used long-acting bronchodilation. GOLD IV subjects 
showed significantly lower ICrest and ICrest/TLC ratios than GOLD II and III subjects 
(Table 1), reflecting more static hyperinflation. According to the MMRC and CCQ 
scores, patients with more severe disease were more disabled.
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Table 1. Patient characteristics.
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GOLD II GOLD III GOLD IV
N 10 12 10
Gender (M/F) 4/6 9/3 6/4
Age (yrs) 66 ±2 67 ±2 66 ±2
BMI (kg/m2) 25.4 ± 1.8 23.9 ± 1.5 23.6 ± 1.2
FEV1 (L) 1.54 ± 0.09 1.17 ± 0.08b 0.75 ± 0.05c,e
FEV1 (%pred) 61 ±3 42±2a 27 ± lc,d
F E VI/FVC (%) 49 ±2 33 ± 2c 27 ± 2c
FRC (%pred) 110 ± 9 126 ±9 127 ± 12
TLC (%pred) 104 ±6 103 ±5 96 ±7
1 Crest (L) 2.62 ±0.19 2.42 ±0.16 1.86 ±0.17a
ICrest/TLC 0.46 ± 0.04 0.38 ± 0.02 0.33 ± 0.02b
DLCO (%pred) 61 ±8 49 ±5 31 ±5b
MMRC 1.3 ± 0.4 1.9 ± 0.4 2.9 ± 0.4a
CCQ 1.5 ± 0.7 2.3 ± 0.9 2.6 ± 1.0a
Data are presented as mean ± SE. CCQ: clinical COPD questionnaire, DLCO: diffusing capacity for 
carbon monoxide, FEV1: forced expiratory volume in 1s, FRC: functional residual capacity, FVC: 
forced vital capacity, GOLD: Global initiative for chronic Obstructive Lung Disease, IC: inspiratory 
capacity, MMRC: modified Medical Research Council dyspnea scale, TLC: total lung capacity. 
a: p<0.05 vs GOLD II, b: p<0.01 vs GOLD II, c: p<0.001 vs GOLD II, d: p<0.05 vs GOLD III, e: p<0.01 
vs GOLD III.
Table 2. End ADL results per GOLD stage.
GOLD II GOLD III GOLD IV
AIC (peak-rest) (L) -0.69 ±0.13 -0.68 ±0.10 -0.43 ±0.11
IRV (L) 0.78 ± 0.09 0.65 ± 0.08 0.51 ±0.09
VE (L/min) 33 ±2 30 ±2 24 ± 2a
BR (L/min) 25 ±3 14 ± 2b 4 ± 1 c,d
BR (%MVC) 43 ±3 31 ±3 14 ± 5c,d
V02 (L/min) 1.00 ± 0.06 0.95 ± 0.09 0.74 ± 0.06
VC02 (L/min) 0.81 ± 0.06 0.75 ± 0.07 0.55 ± 0.04a
Sp02 (%) 92 ± 1 91 ± 1 90 ± 1
Heart rate (beats/min) 106 ±4 104 ±4 102 ±5
ADL time (min) 6.8 ± 0.9 5.9 ± 0.8 3.1 ± 0.8a
Breathing discomfort 3.6 ± 0.5 4.4 ± 0.5 5.7 ± 0.5a
(Borg units)
Data are presented as mean ± SE. ADL: activities of daily living, BR: breathing reserve, AIC: change 
in inspiratory capacity from rest to peak, IRV: inspiratory reserve volume, MVC: maximal voluntary 
capacity, SpO2: oxygen saturation, VE: minute ventilation, VCO2: carbon dioxide production, VO2: 
oxygen uptake.
a: p<0.05 vs GOLD II, b: p<0.01 vs GOLD II, c: p<0.001 vs GOLD II, d: p<0.01 vs GOLD III.
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Activities o f daily living
Activities varied from vacuum cleaning and carrying bags to washing the dishes and 
walking (see online supplement for individual ADL). End ADL results per GOLD stage 
are presented in Table 2. Despite lower peak ventilation, GOLD IV patients reached 
their maximal ventilatory capacity. Carbon dioxide production (VCO2) was lower and 
there was a tendency for a lower VO2 in GOLD IV subjects at the end of the activity 
(p=0.054). The time course of these parameters is shown in Figure 1. No significant 
differences between the groups were seen at isotime (2min) for ventilation, VO2, and 
VCO2 Heart rate and oxygen saturation were similar between the groups.
II n=10 n=10 n=10 n=10 n=9 n=7 n=6
III n=12 n=12 n=11 n=11 n=11 n=8
IV n=10 n=10 n=8 n=4
A ADL time (min)
B ADL time (min)
À-— Ï---- Î» * 1
ADL time (min)
-*■- IV Figure 1. Time course o f  ventila tion  
(A), V02 (B) and VC02 (C) during  
ADL in COPD GOLD stage ll-IV. The 
numbers o f subjects a t each time 
po in t fo r each GOLD group are 
presented. VC02: carbon dioxide 
uptake, VO : oxygen uptake.
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Figure 2. AIC (peak-rest) a t the end o f ADL in COPD GOLD stages ll-IV  w ith  individual pa tien t 
data. IC: inspiratory capacity.
Overall, decrease in IC at the end of the ADL occurred in GOLD II-IV without significant 
difference between the groups (Figure 2, Table 2). There was a tendency for a smaller 
AIC (peak-rest) in GOLD IV. No significant difference in IRV at end ADL was found, 
although only in the most severe group the critical limit of -0.5L (dyspnea limit) was 
reached.626 Figure 3 shows the time course of the operating lung volumes during ADL. 
For operating lung volumes at isotime, no statistically significant difference between 
the groups in AIC (2min-rest) was found. There was a tendency for more DH in GOLD III 
than in GOLD IV subjects. IRV at isotime was smaller in GOLD III and IV compared with 
GOLD II patients (p<0.05 and p<0.01, respectively).
All subjects experienced dyspnea after their ADL. GOLD IV subjects reported the 
highest dyspnea levels (Table 2). Also, ADL time was reduced in the GOLD IV group.
Figure 3. Time course o f operating lung volumes during ADL in COPD GOLD stage II-IV. A t  isotime 
(2min), IRV in GOLD III and IV was significantly low er compared to GOLD II (respectively p<0.05 and 
p<0.01). The numbers o f  subjects a t each time p o in t fo r each GOLD group are presented. Black: 
GOLD IV, gray: GOLD III, lig h t gray: GOLD II. EELV: end expiratory lung volume, IC: inspiratory 
capacity, IRV: inspiratory reserve volume, TLC: to ta l lung capacity, VT: tida l volume.
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Correlations
DH (peak-rest) correlated with ICrest and ICrest/TLC (respectively, r=0.75, p<0.001 and 
r=0.48, p<0.01), but not with FEV1. FEV1 did correlate with IRVpeak (r=0.54, p=0.001). 
Furthermore, DH (peak-rest) correlated with ventilation and tidal volume (r=0.52, 
p<0.01 and r=0.62, p<0.001, respectively).
DISCUSSION
We showed in this study for the first time that DH occurred independent of disease 
severity according to GOLD during real-life ADLs. There was a tendency for less DH in 
the most severe COPD group. The amount of DH was at least partially determined by 
the level of static hyperinflation as reflected by ICrest or ICrest/TLC.
With increasing GOLD stage, scores of disability increased, which was reflected by 
the choice of less heavy tasks (tendency to lower VO2), shorter ADL time, and more 
dyspnea. Activity limitation in the most severe group was probably a combination of 
reaching their dyspnea limit6,26 and minimal breathing reserve. Although GOLD II and 
III participants showed a tendency to greater DH, they did not reach the dyspnea limit 
because of lower operating lung volumes. Also, they did not approach their maximal 
ventilatory capacity. It might be that the patients with most severe disease had less 
possibility for the development of larger amounts of DH because they rapidly reached 
their breathing reserve limitation. However, Vogiatzis et al. showed more DH but 
less ventilation after maximal exercise testing with increasing severity,13 suggesting 
an increased rate of hyperinflation due to more flow limitation. In our study, during 
self-paced ADL, the finding of increasing DH with increasing GOLD stage could not be 
confirmed. However, at isotime there was a tendency for increasing DH with increasing 
GOLD stage, which was blunted in GOLD IV subjects (Figure 3), in conformity with our 
hypothesis. Our results are in line with the conclusions of O'Donnell & Webb, reporting 
a relation between DH during (sub)maximal exercise and static hyperinflation.14 We 
cannot exclude an effect of type of activity on the level of DH in the different GOLD 
stages. However, we showed that DH occurs during real-life daily activities independent 
of GOLD stage, suggesting that DH plays a role in daily activity limitation in COPD. 
Next to ventilatory impairments, other factors, such as muscle dysfunction, might also 
be involved in exercise limitation. Since there is no validated Borg score for whole- 
body muscle discomfort, which would be appropriate in the case of ADLs, we do not 
have information concerning this topic.
DH is believed to be related to dyspnea.6 Indeed, all subjects perceived respiratory 
discomfort at the end of their ADL. However, in an earlier study it was shown that 
change in IRV was the best predictor of change in dyspnea after maximal exercise.5 
Decreased IRV during exercise is the result of static and dynamic hyperinflation. IRV 
after ADL was related to the level of airflow obstruction, suggesting that disease
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severity according to GOLD is related to this most important predictor of dyspnea. 
Dyspnea in turn could lead to decreased physical activity, which was shown to be 
reduced with increasing GOLD stage.3
Although DH is generally believed to play a role in exercise limitation in COPD, some 
found DH to be related with better performance.2728 By means of optoelectronic 
plethysmography it was shown that subjects with DH (defined as an increase in chest 
wall volume, subdivided in rib cage and abdomen) had worse lung function but better 
exercise performance than those without. Subjects without DH decreased abdominal 
volume in contrast to patients with DH, probably by recruiting abdominal muscles, 
resulting in greater work of breathing.27 However, changes in chest wall volume include 
changes in gas volume, gas compression and blood volume,29 and might therefore not 
only reflect DH.
There are some study limitations that need to be addressed. First, measurements 
were performed without strict regulation of medication use, but patients used their 
common medication regimen. Although IC is known to increase after bronchodilation, 
almost all patients used long-acting bronchodilation, which are known to increase 
IC over respectively 12h (beta2-agonists) and 24h (anti-cholinergics).30 31 Furthermore, 
similar DH pre- and post-bronchodilation was found.32'34 Second, although we found 
similar esophageal pressure and TLC before and immediately after exercise, we cannot 
be completely sure whether these parameters changed during the exercise. Since IC 
maneuvers were performed in the upright position, body position did not influence 
our measurements. However, with weight-bearing arm exercise accessory muscle use 
may be limited, which might simulate (further) increments of EELV by a smaller IC 
compared with optimal accessory muscles use. Yet, the minority of the study population 
chose this type of activity. Third, a limit of 10min ADL was used, so some patients 
would have continued their activity normally. However, all subjects who continued for 
10min reached a prolonged steady-state, so physiological parameters would probably 
not change so much. Furthermore, we did not ask for Borg scores during the activity. 
Therefore, we cannot compare physiological parameters at isodyspnea.
In summary, DH occurs independent of GOLD stage during real-life daily activities. 
In contrast, the amount of DH is related to static hyperinflation. The combination of 
static and dynamic hyperinflation, reflected by IRV during exercise, however, does 
get worse with increasing airflow obstruction. IRV might be a better assessor of total 
hyperinflation after activity than just AIC. Our results suggest that DH occurs frequently 
in daily life in patients with moderate to very severe COPD. This limitation might in 
turn contribute to decreased physical activity and health-related quality of life.
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ABSTRACT
Introduction Patients with COPD report more dyspnea during arm than during leg 
exercise. One of the major causes of dyspnea is dynamic hyperinflation (DH), which is 
caused by airflow limitation as well as increase in ventilation. The aim of our study was 
to compare DH at equal ventilation (isoventilation) during arm and leg work and to 
investigate the effects of breathing pattern on DH.
Methods Thirteen clinically stable patients with mild-to-very severe COPD (FEV1 59 
± 21%) participated in this study. Arm and leg constant work rate (CWR) ergometry 
were performed in random order with ventilation equal to that at 50% of peak arm 
load. The corresponding leg load of that level of ventilation was determined from the 
incremental leg test. Respiratory physiology was measured breath-by-breath. Change 
in inspiratory capacity, measured at rest and at 2min intervals, was used to reflect DH. 
Results At steady-state isoventilation (37 ± 2 and 36 ± 2L/min for arm and leg CWR 
tests respectively, p>0.05), arm load was 29 ± 5W and leg load 52 ± 6W (p<0.001). The 
level of DH, 0.32 ± 0.09 and 0.27 ± 0.08L during arm and leg exercise respectively, was 
not significantly different. However, breathing frequency was greater during arm than 
during leg exercise (24 ± 1 versus 21 ± Ibreaths/min, p<0.01) and the opposite was true 
for tidal volume (1.56 ± 0.15 versus 1.69 ± 0.14L, p<0.01).
Conclusions At similar ventilation, we found a similar degree of DH during arm and 
leg CWR tests in patients with mild-to-very severe COPD. Although differences in 
breathing pattern were observed between arm and leg exercise, these did not affect 
the level of DH.
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Chronic obstructive pulmonary disease (COPD) has major impact on exercise capability 
and daily activities, which has important consequences for quality of life.1 Daily 
activities are, for an important part, performed by the arms, and patients report more 
dyspnea during arm than during leg exercise.2
One of the key components of dyspnea is dynamic hyperinflation (DH),3 which is caused 
by airflow limitation and occurs during increased ventilation. Because of decreased 
expiratory airflow in COPD, there is a need for more expiratory time in order to exhale 
the volume of inspired air. However, increase in ventilation during exercise is largely 
dependent on increase in breathing frequency in patients with COPD,4 leading to less 
expiration time with consequent temporary air trapping or DH.
DH during arm exercise may be more pronounced than during leg exercise, because 
of differences in breathing pattern. Ventilation during arm exercise depends more on 
breathing frequency,56 leading to less expiratory time. Work performed by the upper 
body may impede normal recruitment of respiratory muscles, because of interference 
with torso stabilization and arm positioning functions.7 Thus, increase in ventilation 
during arm effort may depend less on increase in tidal volume (chest wall expansion) 
and therefore more on increase in breathing frequency. Furthermore, during arm 
exercise, the alternating use of the expiratory muscles to support expiration may be 
hindered by the continuous activation of these muscles for posture and arm positioning 
purposes, leading to inability to support expiratory flow.
As proposed by above-mentioned theory, DH has indeed been shown to be greater in 
arm than in leg exercise at equal metabolic cost.2 In that study, however, ventilation 
was greater during arm exercise,2 which can explain the greater level of DH. To 
exclude the effect of differences in ventilation at comparable metabolic demand or 
workload in arm and leg exercise on DH, these exercise modes should be compared 
at isoventilation. The aim of our study was therefore to compare DH at isoventilation 
during arm and leg work. It was hypothesized that DH is greater during arm exercise, 
mainly because of greater dependence on breathing frequency to increase ventilation.
METHODS
Subjects
Thirteen clinically stable patients with mild-to-very severe COPD participated in this 
study. Patients were recruited from our in- and outpatient pulmonary rehabilitation 
clinic (before start of rehabilitation). Incremental leg ergometry with arterial blood 
samples was performed, as part of the intake procedure less than six weeks before 
the present study, in accordance with the criteria of the American Thoracic Society on 
cardiopulmonary exercise testing.4 Exclusion criteria were long-term oxygen therapy
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or an exacerbation within four weeks before the study. The study was conducted 
according to the Declaration of Helsinki and approved by the local medical ethical 
committee for human and clinical research. Written informed consent was obtained 
from all participants.
Study design
Subjects visited our laboratory on two different occasions. At the first visit, incremental 
arm ergometry was performed (Lode BV, Groningen, The Netherlands). Predicted peak 
load was 40% of peak leg load (institutional practice) and load was increased every 
minute by predicted peak load/10W until symptom limitation. Ventilation was plotted 
against load for the incremental arm and leg test and ventilation at 50% of peak 
arm load was determined. That level of ventilation was transferred to the leg plot 
(isoventilation) and the corresponding power output was determined (Figure 1).
Figure 1. Ventilation p lo tted  against load fo r incremental leg and arm ergom etry o f  a 
representative patient. A line was drawn a t 50% peak arm load (1). A horizontal line was draw  
crossing the corresponding level o f  ventila tion (2). A fina l line was drawn to ge t the leg load 
matching tha t ventila tion level (isoventilation) (3).
On a second visit, arm and leg constant work rate (CWR) tests at the determined loads 
were performed in random order for 6min to ensure steady-state responses. Between 
the tests, at least 10min of rest was incorporated and ventilation and metabolic 
parameters had to be returned to baseline values.
Patients scored their breathlessness on a 10-point Borg scale at rest and at end exercise.8 
All tests were performed 30min after bronchodilation with 400^g salbutamol.4 
In order to standardize the measurements, arm and leg exercise were performed in 
the form of ergometry. The arm ergometer was positioned on a table in front of the 
subject with the crank centre at shoulder height. The subject was sitting on a stool in 
front of the table, so as to stretch the arms horizontally in turn during cycling. During
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all tests, subjects were asked to pedal with a rate of 60 revolutions per minute.
As part of the characterization procedure, pulmonary function testing was performed 
according to the American Thoracic Society/European Respiratory Society guidelines910 
with thoracic gas volumes determined by body plethysmography11 (Masterlab, Viasys 
Healthcare, Hoechberg, Germany). In addition, body height and weight were assessed 
and body mass index was calculated (weight/height2).
Breathing pattern and respiratory gas exchange
Breathing pattern and respiratory gas exchange were measured using a breath-by-breath 
system (Oxycon Pro, Viasys Healthcare, Hoechberg, Germany),4 which consisted of a face 
mask with turbine and integrated O2 and CO2 electrodes, and electrocardiography and 
pulse oxymetry. Before each test, after 15min of equilibrium, temperature, humidity 
and barometric pressure were determined, and 2-point calibrations of turbine and 
gas analyzers were performed. Prior to exercise measurements, breathing pattern and 
respiratory gas exchange were measured at rest for at least 3min until reaching steady- 
state. Minute ventilation, tidal volume (inspiratory (VT,) and expiratory), oxygen uptake 
and carbon dioxide output were measured breath-by-breath, while heart rate and 
oxygen saturation (forehead probe) were measured continuously. All measurements 
were performed by a trained investigator.
Dynamic hyperinflation
Assuming that total lung capacity remains constant during exercise,1213 change in 
inspiratory capacity (IC) is commonly used to reflect change in end-expiratory lung 
volume and therefore DH.3 IC maneuvers were performed three times at rest (ICrest) 
and the mean was taken.10 During the incremental tests, IC maneuvers were performed 
at peak exercise right before the subject stopped exercising. If the patient indicated 
to reach his/her symptom limitation, or if the investigator -based on her experience- 
indicated near maximum, the patient was stimulated to exercise a few seconds longer 
so a peak IC could be taken. During the CWR tests, IC maneuvers were done at 2min 
intervals (ICCWR1, ICCWR2 and ICCWR3). IC maneuvers were performed in the same upright 
position to avoid influence of body position on total lung capacity and therefore IC. 
After at least four consistent levels of end-expiration, subjects were instructed and 
encouraged to maximally inspire and reach a volume plateau and then to return to 
normal breathing. Performance of the IC maneuver was monitored by the real-time 
display of breathing volumes. For analysis, the IC maneuver together with the preceding 
breaths was placed within the maximal flow-volume curve. Any inconsistency in the 
last breath preceding IC was manually corrected to obtain a true end-expiratory lung 
volume level.14
Steady-state DH was determined by ((ICCWR2+ICCWR3)/2)-ICrest. Inspiratory reserve volume 
(IRV) was calculated as the difference between IC and VTr
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Statistics
Data are presented as mean ± SD (patient characteristics) or mean ± SE. Mean peak 
values of the last 30s of the incremental tests and mean values of the last 3min of CWR 
exercises (steady-state) were used for analyses. Arm and leg ergometry values were 
compared using paired t-tests. A p<0.05 level of statistical significance was used. Data 
were analyzed with SPSS, version 16.0 (SPSS, Chicago, IL).
RESULTS
Subjects
Table 1 shows baseline anthropometric and pulmonary function data of the thirteen 
included patients. Mean forced expiratory volume in one second (FEV1) was 59 ± 21% 
(range 24-91%). Increased functional residual capacity and total lung capacity reflected 
static hyperinflation. Mean smoking history was 31 ± 13 pack years. All patients used 
long-acting bronchodilation and 62% used inhaled corticosteroids.
Table 1. Patient characteristics.
N 13
Gender (M/F) 10/3
Age (yrs) 61 ± 10
BMI (kg/m2) 28.7 ±6.7
FEV1 (L) 1.93 ±0.87
FEV1 (%pred) 59 ±21
FEV1/FVC (% ) 47 ± 9
FRC (%pred) 1 42 ± 29
TLC (%pred) 119 ±21
DLCO (%pred) 56 ± 16
Pa02 (kPa) 10.9 ± 1.5
PaC02 (kPa) 5.0 ± 0.5
Data are presented as mean ± SD. BMI: body mass index, FEV,: forced expiratory volume in one 
second, FRC: functional residual capacity, FVC: forced vital capacity, DLCO: diffusing capacity for 
carbon monoxide, PaO2: arterial oxygen tension, PaCO2: arterial carbon dioxide tension.
Incremental tests
Load at peak leg and arm exercise was 121 ± 15 and 54 ± 7W respectively (p<0.001; 
arm 44 ± 3% of leg exercise). Oxygen uptake and carbon dioxide output at peak arm 
exercise were significantly lower than at peak leg exercise (Table 2). Change in oxygen
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uptake per change in workload was 8 ± Oml/min/W for leg ergometry and 15 ± 1ml/ 
min/W for arm ergometry (p<0.01). The rate of increase in power was significantly 
different during the incremental leg (15 ± 2W/min) and arm (5 ± 1W/min) exercise 
(p<0.001). Ventilation and breathing frequency were lower at peak arm than at peak 
leg exercise, whereas the difference in VT, did not reach statistical significance (Table
2). Correspondingly, expiratory time was greater at peak arm exercise (1.29 ± 0.09 and 
1.06 ± 0.06s for arm and leg respectively; p<0.05). Despite the difference in ventilation 
and breathing pattern, no significant difference between peak arm and leg DH was 
found. The difference in IRV after arm/leg incremental exercise did not reach statistical 
significance (Table 2). Increase of respiratory discomfort was 3.2 ± 0.6 and 4.8 ± 0.5 
Borg units for arm and leg exercise respectively (p<0.05). No difference between arm 
and leg discomfort was found.
Table 2. Physiological characteristics at peak exercise.
Data are presented as mean ± SE. IC: inspiratory capacity, IRV: inspiratory reserve volume, RER: 
respiratory exchange ratio, SpO2: oxygen saturation, VCO2: carbon dioxide output, VE: minute 
ventilation, VO2: oxygen uptake, VTI: inspiratory tidal volume. 
a: p< 0.001, b: p< 0.05.
Constant work rate tests 
Workload and oxygen uptake
At isoventilation, load at arm CWR was 29 ± 5W (50% of peak arm load), whereas 
leg CWR load was 52 ± 6W (p<0.001). Oxygen uptake and carbon dioxide output 
were significantly greater for leg than for arm steady-state exercise. The respiratory
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exchange ratio was greater during arm exercise (Table 3). Figure 2A presents the time 
course of oxygen uptake during both types of exercise. Change in oxygen uptake per 
change in workload during arm exercise was more than twice that during leg exercise 
(20 ± 4ml/min/W and 9 ± 1ml/min/W respectively, p<0.05).
Minute ventilation and its determinants
As determined by our protocol, ventilation was equal during arm and leg CWR testing 
(Figure 2B). However, breathing frequency at steady-state was greater during arm than 
during leg exercise (Figure 2C). The opposite was true for VTI (Figure 2D). Inspiratory 
flow was significantly larger and expiratory time was smaller for arm than for leg 
steady-state exercise (both p<0.05; Table 3). No differences were observed in the duty 
cycle (ratio of inspiratory and total respiratory cycle time) (Table 3).
Table 3. Physiological characteristics at isoventilation constant 
work rate exercise.
Leg Arm
Load (W) 52 ±6 29 ± 5a
V02 (L/min) 1.14 ±0.06 0.99 ± 0.04a
VC02 (L/min) 1.05 ± 0.06 0.96 ± 0.05b
RER 0.92 ± 0.02 0.96 ± 0.02c
Heart rate (beats/min) 109 ±5 114 ± 6c
Sp02 (%) 96 ± 1 97 ± 1
VE (L/min) 36 ±2 37 ±2
Breathing frequency 21 ± 1 24 ± lb
(breaths/min)
VTI (L) 1.69 ±0.14 1.56 ± 0.15b
TI (s) 1.11 ±0.07 0.99 ± 0.07a
TE (s) 1.78 ±0.10 1.59 ± 0.08c
TTOT (s) 2.89 ±0.15 2.58 ±0.14c
TI/TTOT 0.38 ±0.01 0.38 ±0.01
Inspiratory flow (L/s) 1.52 ± 0.08 1.58 ± 0.08c
Expiratory flow (L/s) 0.98 ± 0.08 1.00 ± 0.07
AIC (end-rest) (L) -0.27 ± 0.08 -0.32 ± 0.09
IRV (L) 1.13 ± 0.17 1.27 ± 0.18c
Data are presented as mean ± SE. IC: inspiratory capacity, IRV: inspiratory reserve volume, RER: 
respiratory exchange ratio, SpO2: oxygen saturation, TE: expiratory time, TI: inspiratory time, TTOT: 
inspiratory + expiratory time, VCO2: carbon dioxide output, VE: minute ventilation, VO2: oxygen 
uptake, VTe: expiratory tidal volume, VTI: inspiratory tidal volume. 
a: p< 0.001, b: p< 0.01, c: p< 0.05.
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Dynamic hyperinflation and its consequences
In contrast to our hypothesis, the level of DH expressed as change in IC, -0.32 ± 0.09 and 
-0.27 ± 0.08L during arm and leg CWR exercise respectively, was not significantly 
different at isoventilation (Figure 3). Steady-state IRV was significantly greater for arm 
than for leg exercise (p<0.05). Increase in breathing discomfort was similar at arm and 
at leg steady-state exercise (1.6 ± 0.5 versus 2.2 ± 0.3 Borg units respectively, p>0.05), as 
was arm/leg discomfort (2.5 ± 0.4 versus 2.2 ± 0.5 Borg units, p>0.05).
Change in IC at CWR arm exercise was significantly smaller than at peak arm exercise 
(-0.32 ± 0.09 versus -0.60 ± 0.12L; p<0.01). The same was true for the CWR and peak leg 
exercise (-0.27 ± 0.08 versus -0.59 ± 0.15L; p<0.05).
DISCUSSION
The main finding of this study is that equal DH developed during CWR arm and leg 
ergometry at isoventilation in patients with mild-to-very severe COPD, despite a 
greater dependence on breathing frequency with consequent less expiratory time 
during arm exercise. Therefore, we have to reject our hypothesis. From a mechanistic 
point of view, comparing arm and leg exercise at equal levels of ventilation contributes 
to the physiologic understanding of these different exercise types.
Operating lung volumes, for example DH and IRV, are important determinants of 
dyspnea.315 In contrast to similar DH, IRV during CWR arm exercise was greater than 
during leg exercise, mainly because of a smaller VTr However, during neither kind of 
exercise the critical limit of 0.5L for IRV was reached.15 Accordingly, we did not find 
greater breathing discomfort during arm exercise at isoventilation. However, during 
'comparable' arm and leg exercise, e.g. at equal workload or oxygen uptake, reported 
dyspnea during arm exercise is greater.2 Increased dyspnea during arm activity under 
these circumstances might be explained by the greater increase in ventilation,216 
resulting in more DH and a lower breathing reserve.
Repeated IC measurements have been shown to be a reliable method to track DH during 
different types of exercise.121317 Furthermore, maximal transdiaphragmatic pressure 
and total lung capacity have been shown to be independent of arm position,1819 
suggesting that muscle competition does not impede the capability to perform IC 
maneuvers and that IC does not change due to a change in total lung capacity. 
Breathing frequency was significantly greater and VT, was smaller during arm compared 
to leg work at equal ventilation. This could be explained by thoracic muscle use for 
arm positioning and posture leading to a stiffer thorax, which makes it more difficult 
to expand tidal volume and leads to a greater dependence on breathing frequency. 
Increased respiratory rate may lead to greater flow resistive forces and physiological 
dead space ventilation with possible negative consequences for expiratory flow.
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Figure 2. Oxygen consumption (A), ventila tion (B), breathing frequency (C) and tida l volume (D) 
during isoventilation leg and arm constant work rate ergometry (27 ± 5 and 51 ±5 W respectively).
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Figure 3. Inspiratory capacity during isoventilation leg and arm constant work rate ergometry. 
IC: inspiratory capacity.
On the other hand, increased respiratory rate leads to a stiffer thorax, which may 
support expiratory flow, but complicate inspiratory flow. Expiratory flow was similar 
during the two types of exercise, but inspiratory flow was somewhat larger during arm 
exercise -probably in an attempt to create more expiratory time- despite the suggested 
increase in stiffness of the thorax. However, the duty cycle was similar with the arm 
and leg CWR tests.
Variable results have been reported when comparing peak arm and leg test values in 
patients with COPD. Some found significantly lower peak arm load, oxygen uptake, 
and ventilation than peak leg values (62%, 83%, and 86% of peak leg respectively,20 
and 82%, 85%, and 89% of peak leg respectively.21) Others found no significant 
differences in patients with COPD, but lower peak arm than peak leg values (load 
58%, oxygen uptake 73%, and ventilation 80%) in healthy subjects, suggesting that 
the upper limbs are less affected in COPD patients.22 In the present study, the ratio of 
peak arm compared to peak leg load (44%) was considerably lower, which might be 
due to our population (on average milder COPD than in the described studies). The 
change in oxygen uptake per change in load at incremental arm exercise was almost 
twice that during leg exercise, which may be partly explained by the smaller rate of 
increase in power during arm exercise, producing a greater delta oxygen uptake/delta 
load ratio.23 However, the ratio during the arm CWR test was more than twice that 
during the CWR leg test, suggesting that differences in muscle fiber type and mass 
used during exercise may also play a role. Less efficient oxygen use during arm exercise 
may lead to an early anaerobic threshold with consequent increase in ventilation.
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The similar DH at peak arm and leg exercise was accompanied by a smaller level of 
ventilation during the arm test, and therefore a greater rate of DH, i.e. the change in 
IC per change in ventilation. At CWR isoventilation, however, this greater rate was not 
confirmed by more DH during arm work.
There are some study limitations that need to be addressed. First of all, ergometry was 
used as a model of daily activity. However, during arm ergometry the bulk of weight 
is supported, which is not the case in daily life. Therefore, our results cannot simply 
be extrapolated to daily life. Nevertheless, to standardize the protocol, ergometry 
was used. Furthermore, in order to reach steady-state isoventilation, ventilation was 
relatively low for leg exercise. Greater differences in breathing pattern accompanied 
by more, and possibly differences in DH might have developed if greater levels of 
isoventilation could have been sustained until steady-state. However, despite relatively 
low ventilation, DH occurred even in milder patients. A very recent study found no DH 
during a CWR arm test at 50% peak load in more severely affected patients with COPD, 
in contrast to DH development at 65% and 80% peak load.24 A final limitation of our 
study is that the Borg score for arm discomfort is not validated.
Conclusion
We found a modest and similar degree of DH during arm and leg endurance tests at 
equal ventilation in patients with mild-to-very severe COPD. Although differences in 
breathing pattern were found between arm and leg exercise, these did not affect the 
level of DH.
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DYNAMIC HYPERINFLATION AFTER METRONOME-PACED HYPER­
VENTILATION IN COPD - A  2 YEAR FOLLOW-UP
Respir Med 2010;104:1700-1705.
ABSTRACT
Introduction In contrast to the decline in FEV1; the behavior of dynamic hyperinflation 
(DH) over time is unknown in patients with COPD. Metronome-paced hyperventilation 
(MPH) is a simple applicable surrogate for exercise to detect DH. The aim of this study 
was to evaluate changes in MPH-induced DH during two years follow-up in mild-to- 
severe COPD patients. Additionally, influence of smoking status on DH and the relation 
between DH and other lung function parameters was assessed.
Methods Patients were recruited from a randomized controlled trial conducted in 
general practice. Measurements of lung function and DH were performed at baseline 
and after 12 and 24 months. DH was assessed by MPH with breathing frequency set at 
twice the baseline rate. Change in inspiratory capacity after MPH was used to reflect 
change in end-expiratory lung volume and therefore DH, presuming constant total 
lung capacity.
Results During follow-up, 68 patients completed all measurements. DH increased by
0.23 ± 0.06L (p<0.001). No significant changes in FEV1 %pred were seen. Smokers had 
lower FEV1 and a more rapid decline than non-smokers. DH in smokers increased more 
over time compared to non-smokers. The amount of DH correlated positively with 
resting inspiratory capacity.
Conclusions After two years, significant increase in MPH-induced DH in COPD patients 
was demonstrated, which was not accompanied by a decline in FEV1. It might be that 
DH is a more sensitive measure to track consequences of changes in airflow obstruction.
Boek Jorien.indb 55 18-4-2011 12:36:08
INTRODUCTION
Boek Jorien.indb
Chronic obstructive pulmonary disease (COPD) is a progressive disease with major 
impact on individual patients' quality of life. According to American Thoracic Society/ 
European Respiratory Society (ATS/ERS) consensus statements, forced expiratory 
volume in 1s (FEV1) is used worldwide to diagnose and stage COPD.1 FEV1 and the rate 
of its decline are both predictors of mortality.2,3 However, this parameter of disease 
progression fails to be a reliable predictor of patient centered outcomes like exercise 
tolerance, dyspnea or health-related quality of life.4 In these outcomes, changes in 
operating lung volumes appear to play a more important role.5 The origin of these 
changes in lung volumes is dynamic hyperinflation (DH), which is defined as a transient 
increase in end-expiratory lung volume (EELV) as a result of increasing ventilation with 
concomitant expiratory flow limitation. In contrast to the decline in FEV1 over time, 
reflecting the progression in disease, the behavior of dynamic lung volumes over time 
is unknown.
One explanation for this lack of information might be that measurements of DH 
during exercise are quite time consuming. DH is commonly estimated by measuring 
change in inspiratory capacity (IC) during exercise, which reflects change in EELV. 
Gelb et al. compared DH after incremental cycle ergometry and metronome-paced 
hyperventilation (MPH) in COPD patients.6 IC was measured at rest and immediately 
after 20s MPH with breathing frequency set at twice the resting rate.6 The change in 
IC after MPH was comparable to the change in IC after incremental cycle ergometry. 
Therefore, MPH is a simple applicable surrogate for exercise to detect DH. This offers a 
practical solution to study changes in DH over time. The purpose of the present study 
was to evaluate changes in MPH-induced DH during two years of follow-up in patients 
with COPD. In addition, the influence of smoking status on DH was explored and the 
relation between DH and other lung function parameters was assessed.
METHODS
Subjects
Patients were recruited from a randomized controlled trial comparing three different 
modes of COPD disease management in general practice conducted by the Department 
of Primary and Community Care of the Radboud University Nijmegen Medical Centre. 
Details of this trial are described at http://ClinicalTrials.gov, Identifier NCT00128765. 
Inclusion criteria were mild-to-severe COPD according to the Global initiative for 
chronic Obstructive Lung Disease (GOLD) classification1 and age >35 years. Exclusion 
criteria were GOLD stage IV, treatment by a chest physician and severe comorbidity 
with reduced life expectancy. An additional exclusion criterion for the present study 
was the inability to visit our pulmonary function unit. This study was approved by the 
local medical ethics committee. All participants gave written informed consent.
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Study design
In the present study, IC measurements and spirometry were the primary outcomes. 
Measurements were performed at baseline and after 12 and 24 months. Patients were 
free of exacerbation during testing. Prescriptions for pulmonary medication during 
the study were extracted from the general practitioners' medical records.
Spirometry and IC measurements
Patients were instructed to continue their usual medication, but to withhold short- 
acting beta2-agonists and/or anti-cholinergics for 6 and 8h respectively and long-acting 
beta2-agonists and/or anti-cholinergics for 12 and 24h respectively prior to testing. 
Pulmonary function was measured using a spirometer (Masterlab, Viasys Healthcare, 
Hoechberg, Germany) according to the guidelines of the ATS/ERS.7 IC maneuvers were 
performed before and immediately after 20s MPH with breathing frequency set at 
twice the current resting rate.6 Patients were instructed to take a deep breath in after 
normal exhalation and encouraged to inspire maximally (to the total lung capacity 
(TLC)). During MPH, patients were encouraged to maintain a tidal volume (VT) equal 
to resting VT. Performance of the test was monitored by the real-time display of 
breathing volumes. Any inconsistency in the last breath preceding the IC was manually 
corrected to obtain a true EELV.8
Repeatability of the IC's has been tested in a subgroup. In 18 patients, the mean 
coefficients of variation of resting IC (ICrest) and IC after MPH (ICMPH) were 2.6 ± 1.8% 
and 3.3 ± 3.1% respectively.
Spirometry and IC maneuvers were repeated after administration of 80^g 
ipratropium/400^g salbutamol. If not stated otherwise, post-bronchodilation values 
are presented in the results.
Predicted ICrest was calculated as predicted TLC minus the predicted functional residual 
capacity. Change in IC (AIC: ICMPH-ICrest) was used to reflect DH, presuming constant 
TLC.9,10 Inspiratory reserve volume (IRV) was calculated as IC-VT. Minute ventilation was 
calculated by breathing frequency x VT.
Statistical analysis
Data are expressed as mean ± SE. Changes in lung function parameters and DH over 
time were analyzed with general linear models for repeated measures (two-factor 
mixed design: time and group). Post hoc analyses were performed with Bonferroni 
(time) and Scheffe (group) corrections for multiple comparisons. Differences between 
pre- and post-bronchodilation values were tested with a two-way repeated measures 
design. Pearson correlation coefficient was used to evaluate associations between 
lung function parameters and DH. Statistical significance was set at p<0.05. Data were 
analyzed with SPSS, version 16.0 (SPSS, Chicago, IL).
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RESULTS
Study population
After initial screening, 124 patients were included in the current study. During two 
years of follow-up, 68 patients completed all measurements (Figure 1). Reasons 
for drop-out were the incapacity to visit our laboratory (n=15), the occurrence of 
comorbidity with reduced life expectancy (n=3), death (n=4), software problems (n=9) 
or unknown (n=25).
Figure 1. Overview o f the number o f participants initially included and those remaining after 
two years.
Patient characteristics
Sixty-eight patients (GOLD I n=8, GOLD II n=47, GOLD III n=13) had complete follow- 
up. Seventy-two percent of the study population was male. Mean age at baseline was 
64 ± 1 years and body mass index was 26.4 ± 0.5kg/m2.
Patients who were excluded because of missing data or withdrawal had similar 
baseline characteristics as those with complete data sets (data not shown). Twenty- 
nine percent used any long-acting bronchodilator and 16% used tiotropium. Mean 
post-bronchodilation FEV1 at baseline was 66% of predicted. Mean MPH-induced AIC 
at baseline was -0.44L.
Differences between management groups during follow-up
Patient characteristics, lung function parameters and DH were similar between the 
disease management groups during baseline and two year follow-up. In addition, 
prescription of long-acting bronchodilation and drop-out rate were comparable 
between the management groups. Therefore, follow-up analyses are described 
without separate group values.
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Course of lung function parameters and dynamic hyperinflation 
Pre- and post-bronchodilation results are presented in Table 1A and B respectively. Post- 
bronchodilation values of FEV1 (L and %pred), ICrest (L and %pred), IRV after MPH, 
ventilation after MPH and change in ventilation from rest to MPH (Aventilation) were 
significantly greater than pre-bronchodilation values at all time points (all p<0.001). 
The rate of DH (AIC/Aventilation) was significantly smaller after bronchodilation 
(p<0.001).
Table 1A. Pre-bronchodilation follow-up lung function parameters.
All values are mean ± SE. FEV1: forced expiratory volume in 1s, IC: inspiratory capacity, A: MPH- 
rest, IRV: inspiratory reserve volume, MPH: metronome-paced hyperventilation, VE: ventilation. 
a: p<0.05 versus baseline, b: p<0.05 versus 12 months.
Table 1B. Post-bronchodilation follow-up lung function parameters.
Baseline 12 months 24 months
FEV1 (L) 1.92 ± 0.07 1.87 ± 0.07 1.86 ± 0.07a
FEV1 (%pred) 66 ±2 64 ±2 65 ±2
ICrest (L) 2.93 ± 0.08 2.96 ± 0.09 3.09 ± 0.09a
ICrest (%pred) 105 ±2 107 ±3 112 ± 2b
AIC (L) -0.44 ± 0.04 -0.49 ± 0.04 -0.66 ± 0.05c,d
IRV MPH (L) 1.53 ± 0.07 1.47 ± 0.07 1.41 ±0.06
VE MPH (L/min) 28.6 ± 1.4 30.9 ± 1.4 32.7 ± 1.5b
AVE (L/min) 15.9 ± 1.1 17.2 ± 1.1 14.9 ± 1.0
AIC/AVE (L/L/min) -0.04 ± 0.00 -0.03 ± 0.00 -0.07 ± 0.01 c,e
All values are mean ± SE. FEV1: forced expiratory volume in 1s, IC: inspiratory capacity, A: MPH- 
rest, IRV: inspiratory reserve volume, MPH: metronome-paced hyperventilation, VE: ventilation. 
a: p<0.05 versus baseline, b: p<0.01 versus baseline, c: p < 0.001 versus baseline, d: p<0.05 versus 
12 months, e: p<0.01 versus 12 months.
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During the two years follow-up there was no significant decrease in post-bronchodilation 
FEV1 %pred, although absolute FEV1 slightly decreased (0.06 ± 0.02L, 95%CI 0.00-0.12; 
p<0.05) (Table 1B). ICrest improved significantly during follow-up with 7 ± 2%pred 
(95%CI 1.9-11.7; p<0.01).
MPH-induced DH increased by 0.23 ± 0.06L (95%CI 0.09-0.37L; p<0.001) during the two 
year follow-up period (Table 1B). VT did not change over time and breathing frequency 
at rest and during MPH increased slightly from baseline to 24 months (1 and 2 breaths/ 
min respectively; p<0.05). This resulted in higher minute ventilation at 24 months 
(Table 1B). However, change in ventilation from rest to MPH did not significantly differ 
between baseline and follow-up measurements. Furthermore, when AIC was expressed 
per change in ventilation, a higher rate of DH was shown during follow-up. IRV after 
MPH did not change significantly over time.
Sixty-three percent of the patients had at least one prescription for any long-acting 
bronchodilator during the study. These patients had lower FEV1 %pred than those 
who did not have a long-acting bronchodilator prescription (p<0.05), but the rate of 
decline was equal. ICrest was comparable between these groups. The 40% of patients 
receiving at least one prescription for tiotropium, also had smaller FEV1 %pred (p<0.01) 
than those who were not prescribed tiotropium. FEV1 %pred rate of decline and ICrest 
was similar among these groups.
Influence of smoking status
The group of current smokers (n=27) had a different gender distribution compared 
to current non-smokers (n=41) (56 and 83% male respectively; p<0.001). Furthermore, 
smokers were younger than non-smokers (age 61 ± 1 and 66 ± 1 years respectively; 
p<0.05). Therefore, only relative measures were used for comparisons between these 
groups. Smokers had smaller FEV1 values and a more rapid decline (Figure 2A). Resting 
IC at baseline was 99 ± 4%pred in smokers and 109 ± 3%pred in non-smokers (p<0.001), 
but improved equally in both groups. Ventilation and change in ventilation from rest 
to MPH were similar in the groups. DH in smokers increased more over time (Figure 
2B). This did not result in a significant difference in IRV between the groups.
Correlations
FEV1 correlated with ICrest at baseline, 12 and 24 months (r=0.53, 0.49, 0.65 respectively; 
all p<0.001) (Figure 3). ICrest (L) correlated with AIC (r=-0.44, -0.43, -0.52 respectively; 
all p<0.001) and IRV after MPH (r= 0.59, 0.59, 0.65 respectively; all p<0.001). Thus, larger 
ICrest was associated with more DH, but with greater IRV after MPH. No correlation 
was found between FEV1 and AIC. However, FEV1 %pred did correlate with the rate of 
DH (r=0.36, 0.42 at baseline and 12 months; p<0.01 and <0.001 respectively).
In the smokers subgroup a correlation between FEV1 %pred and AIC at baseline and 12 
months was found (r=0.43 and r=0.54 respectively, both p<0.05).
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Figure 2. A: FEV1 %pred at baseline, 12 and 24 months for smokers and non-smokers. B: AIC after 
MPH at baseline, 12 and 24 months for smokers and non-smokers. AIC: ICMPH-ICrest, FEV1: forced 
expiratory volume in 1s, IC: inspiratory capacity, MPH: metronome-paced hyperventilation.
Figure 3. Correlation between FEV1 and ICrest at 24 months. FEV1: forced expiratory volume in 
1s, IC: inspiratory capacity.
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This is the first study describing changes in DH over time in patients with mild-to- 
severe COPD. We followed 68 patients recruited from general practice for two years 
and found an increase in MPH-induced DH of 0.23L. Also, AIC/Aventilation, the rate of 
DH, increased during follow-up. Subgroup analysis revealed that smokers had a more 
rapid increase of DH over time than non-smokers.
It was hypothesized that DH develops only when COPD becomes severe.11 In our 
subjects, increase in DH over time was not accompanied by a decline in FEV1 %pred. 
Furthermore, even our milder patients already showed DH, in line with recent findings 
of occurrence of DH in mild and moderate COPD.1213 Together, these findings rather 
contradict the hypothesis of the development of DH in the natural history of COPD, 
though we recognize the fact that three measurements in two years may be too short 
to represent natural history.
The steeper increase in DH in smokers was accompanied by a faster decline in FEV1, 
suggesting that in this subgroup airflow obstruction, as reflected by FEV1, does 
contribute to the level of DH. DH is a consequence of airflow limitation, which however 
may not be represented entirely by FEV1. It might be that additional parameters of 
flow obstruction as derived by the appliance of negative expiratory pressure14 or 
measures of peripheral obstruction better reflect airflow limitation. DH could be a 
sensitive measure to express the consequences of changes in airflow obstruction. 
ICrest correlated with MPH-induced DH, which is comparable to earlier findings in which 
resting IC correlated with DH at peak exercise.15 This supports the idea that the amount 
of DH might be partially determined by resting volumes, thus, the more space the more 
DH. Resting IC slightly increased during follow-up, which might be due to increased 
long-acting bronchodilator use.16'18 Sixty-three percent of the subjects had a long- 
acting bronchodilator prescribed during follow-up. Although patients stopped their 
long-acting beta2-agonists and/or anti-cholinergics for 12 and 24 h respectively prior 
to measurements, there might still be an effect on ICrest.16’18 However, no differences 
in ICrest were found between those who did and did not receive a prescription for a 
long-acting bronchodilator. Since information on the actual use of these medications 
is lacking, this conclusion has to be interpreted with caution. We cannot exclude the 
possibility that the small increase in ICrest occurred due to an increase in TLC.
In our study, post-bronchodilation MPH-induced DH was approximately 0.5L at all time 
points. O'Donnell et al. demonstrated that exercise-induced DH of ~0.5L was associated 
with a steep increase in dyspnea intensity.19 This 0.5L limit for DH was obtained in 
severe patients with COPD with an IRV of ~0.5L after exercise, which also has been 
associated with a strong increase in dyspnea.19 Change in IRV has been shown to be the 
best predictor of dyspnea after exercise and leads to neuromechanical dissociation.20 21 
A greater tolerance of DH after bronchodilation versus placebo19 indicates that
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relevant DH probably cannot be represented by a fixed amount. Probably, DH together 
with decreased resting IC leads to a critically small IRV and therefore to dyspnea with 
consequent exercise intolerance.
In our study, IRV after MPH did not reach the critical limit of ~0.5L.19,20 This might be 
partially explained by a lower VT during MPH compared to exercise. The low VT/IC 
ratio after MPH (~0.4) indicates that there would have been more room to expand VT. 
However, Ofir et al. have shown that even with greater VT, IRV is preserved in milder 
patients. They studied patients with comparable resting IC, equal amounts of DH, but 
greater VT/IC ratios (~0.7) during peak exercise. Despite larger VT, those subjects did not 
reach the critical limit of IRV.12 This supports our idea that the relatively large resting 
IC is the main reason that a critical IRV is not reached during MPH in our population. 
There are some study limitations that need to be addressed. Our population was subject 
to a disease management intervention. No differences between the management 
groups in patient characteristics, and lung function indices and MPH-induced DH over 
time were seen. However, there might be an overall positive in-study effect on lung 
function. Furthermore, we did not assess TLC. The IC/TLC ratio at rest would have given 
an additional description of static hyperinflation. Also, ventilation increased over time, 
which suggests some bias in the increase in DH. However, change in ventilation from 
rest to MPH did not alter and the rate of DH (AIC/Aventilation) increased, which is 
consistent with the increase in DH. Finally, drop-out was considerable, ~40%, which 
compromises generalizability of the results, but was comparable with other COPD 
trials.22,23
In conclusion, after a two year follow-up significant increase in MPH-induced DH in 
patients with mild-to-severe COPD was demonstrated, in the absence of change in 
FEV1 %pred. It might be that DH is a more sensitive measure to track consequences of 
changes in airflow obstruction.
Future studies should be directed at elucidating factors that determine DH and at 
investigating the clinical relevance of DH, especially in patients with mild and moderate 
COPD.
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NON-INVASIVE VENTILATION ABOLISHES THE IL-6 RESPONSE TO 
EXERCISE IN COPD PATIENTS
Submitted.
ABSTRACT
Introduction Systemic inflammation in patients with chronic obstructive pulmonary 
disease (COPD) has been related to the development of comorbidities. The level of 
systemic inflammatory mediators is aggravated as a response to exercise in these 
patients. We aimed to investigate whether unloading of the respiratory muscles could 
attenuate the inflammatory response to exercise in COPD patients.
Methods A cross-over design was used in which eight muscle-wasted (i.e. fat free mass 
index <16kg/m2 for men and <15kg/m2 for women) stable COPD patients performed 
40W constant work rate cycle exercise with and without non-invasive ventilation­
support (NIV versus control). Patients exercised until symptom limitation for maximally 
20min. Arterial blood samples were taken at rest, immediately after exercise or at 
isotime when patients exercised longer during the second test. Two-way repeated 
measures were performed to evaluate differences between the responses to both 
exercise modes.
Results Duration of control exercise and exercise with NIV-support was similar, both 
12.9 ± 2.8min. IL-6 plasma levels increased significantly by 25 ± 9% in response to 
control exercise, but not in response to NIV-supported exercise. Accordingly, the IL-6 
response to NIV-supported exercise differed significantly from the exercise-induced 
IL-6 response under control conditions (p<0.05). Leukocyte concentrations increased 
by ~15% both after control and NIV-supported exercise (p<0.05), without differences 
between both responses. The capacity of blood cells to produce reactive oxygen 
species and plasma concentrations of C-reactive protein and carbonylated proteins 
were neither affected by control nor by NIV-supported exercise.
Conclusions The present study demonstrates that NIV abolishes the IL-6 response to 
submaximal exercise in muscle-wasted patients with COPD. These data suggest that 
the respiratory muscles contribute to exercise-induced IL-6 release in these patients.
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Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow 
limitation.1 Yet, increasing evidence indicates that COPD also includes severe systemic 
manifestations, like skeletal muscle dysfunction and cardiovascular impairments.2 
Many of the systemic consequences of COPD have been related to the presence of 
systemic inflammation.3 While the degree of systemic inflammation in COPD patients 
at rest has been marked as low grade, several studies have demonstrated that exercise 
aggravates the level of systemic inflammatory mediators.45 The systemic inflammatory 
response to exercise in COPD patients even occurs after submaximal exercise, like a 
6min walk test.6
Considering the important role of systemic inflammation in the pathogenesis of 
COPD, it seems therapeutically attractive to attenuate the inflammatory response to 
exercise. Although the exact origin of the inflammatory response is currently unclear, 
a potential role has been ascribed to the respiratory muscles.7 During exercise, the 
respiratory muscles of patients with COPD are excessively loaded.8 Increased loading of 
the respiratory muscles, even in the absence of total body exercise, leads to a systemic 
inflammatory response.7 Therefore, we aimed to investigate whether unloading of the 
respiratory muscles could attenuate the inflammatory response to exercise in patients 
with COPD.
Non-invasive ventilation (NIV) is a commonly used intervention to unload the respiratory 
muscles.9'11 Several studies have shown that NIV improves exercise tolerance in COPD 
patients.1112 Yet, the effect of NIV on the inflammatory response to exercise has never 
been studied. We hypothesized that the inflammatory response to exercise in patients 
with COPD could be suppressed by the appliance of NIV. We aimed the outcomes of 
the current study to be of clinical use during for example pulmonary rehabilitation 
and activities of daily life. Therefore, we chose to investigate systemic inflammation 
as a response to submaximal exercise and to adjust NIV settings non-invasively and 
practically applicable, i.e. according to patients comfort.
METHODS
Subjects
Since the inflammatory response to exercise is known to be more pronounced in 
muscle-wasted than in non-muscle-wasted COPD patients,13 the current study included 
muscle-wasted COPD patients to study the effect of NIV.
Eight muscle-wasted (fat free mass index <16kg/m2 for men and <15 kg/m2 for women14) 
patients with stable COPD were included in this study. Patients were recruited 
from our outpatient clinic. Exclusion criteria were current smoking, other systemic 
inflammatory diseases, exercise-limiting co-morbidity, long-term oxygen therapy,
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respiratory insufficiency, the use of oral corticosteroids, an exacerbation within six 
weeks before the study, or the absence of ventilatory limitation during control exercise 
at 40W.15 Since anti-oxidant supplementation may affect the inflammatory response 
to exercise,16 the use of N-acetylcysteine (in two patients) and supplemental vitamins 
(in three patients) was discontinued at least one week before start of testing. The 
study was conducted according to the Declaration of Helsinki and was approved by 
the medical ethical committee of our hospital. Written informed consent was obtained 
from all participants.
Study design
As part of the characterization procedure, pulmonary function testing (Masterlab, 
Viasys Healthcare, Hoechberg, Germany) was performed.17
In two subsequent visits, the systemic responses to exercise with NIV compared to 
control were evaluated in a cross-over design. At both visits, patients performed 
constant work rate cycle exercise until symptom limitation, or for maximally 20min. In 
order to simulate daily life activities and to standardize the exercise, ergometry was 
performed at 40W.18 Heart rate was measured continuously by electrocardiography. 
An arterial cannula was inserted into the brachial artery under local anesthesia at 
each visit. Arterial blood samples were drawn at rest and immediately after exercise 
(max) for determination on blood gases and markers of systemic inflammation and 
oxidative stress. Arterial blood gases and lactate levels were analyzed immediately 
after sampling using Bayer Rapidlab 865 blood gas analyzer (Leverkusen, Germany). 
Measurements after exercise were corrected for plasma volume shifts according to Dill 
and Costill.19 In addition, patients scored their breathlessness and leg discomfort on a 
10-point Borg scale at rest and at max.
During the first visit (control visit), minute ventilation was measured using Oxycon 
Pro (Viasys Healthcare, Hoechberg, Germany). Mean minute ventilation during control 
exercise was 90 ± 10% of predicted maximal ventilation (37.5xforced expiratory 
volume in 1s (FEV1)15). At the end of the first visit, NIV (VPAP III, Resmed, Bella Vista, 
Australia; bi-level positive airway pressure modus) with a tight-fitting partial face 
mask, was introduced in order to become familiarized with it for the second visit. 
Accordingly, inspiratory positive airway pressure (IPAP) and expiratory positive airway 
pressure (EPAP) were adjusted on the basis of patient comfort at rest.20 The mean 
level of IPAP was 12.0 ± 0.8cmH2O (range 10-14cmH2O) and the mean EPAP was 5.0 
± 0.4cmH2O (range 4-6cmH2O). At the second visit, NIV was applied during the 40W 
constant work rate exercise testing. The rest blood sample was taken before starting 
NIV. The max blood sample was drawn immediately after exercise or at isotime when 
patients exercised longer than during control exercise to exclude an effect of exercise 
time. The second visit occurred within two weeks after the first visit. Because constant 
work rate cycle test-retests have been shown to be highly reproducible in patients with
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COPD,21 we anticipated that exercise capacity at the two visits were comparable. All 
measurements were performed by a trained investigator.
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Markers of systemic inflammation and oxidative stress
Quantitative determination of interleukin (IL)-6 was performed using high-sensitivity 
enzyme-linked immuno sorbent assay (ELISA) in kit form (Quantikine® HS, R&D systems, 
MN). Leukocyte and neutrophil count were determined according to standardized 
clinical laboratory assays. High-sensitivity C-reactive protein (hsCRP) levels were 
determined by nephelometry (Siemens Dade Behring, Deerfield, IL).
Production of reactive oxygen species (ROS) by whole blood in response to 
stimulation with phorbol myristate acetate (PMA) was evaluated by luminol- 
enhanced chemiluminescence measured in an automated luminometer (Microplate 
Luminometer LB 96V, EG&G Berthold, Vilvoorde, Belgium), as described previously.22 
The peak oxygen radical production (relative light units (RLU)/s) was calculated. Levels 
of protein carbonyls, a marker of protein oxidation, were measured by means of ELISA 
as described previously.23
Statistics
Data are presented as mean ± SE. To establish that patients' conditions were comparable 
before both exercise conditions, paired Student t-testing was performed on values 
at rest. The responses to exercise, for each exercise mode, were also evaluated by 
paired Student t-testing. Two-way repeated measures (doubly multivariate repeated 
measures) were performed to test whether an interaction-effect between exercise and 
intervention existed, i.e. a difference in the responses to control exercise and NIV- 
supported exercise. A p-value less than 0.05 was considered statistically significant. 
Data were analyzed with SPSS, version 16.0 (SPSS, Chicago, IL).
RESULTS
Subjects
Table 1 shows baseline anthropometric and pulmonary function data of the eight 
included muscle-wasted COPD patients. Mean FEV1 was 42 ± 6% of predicted values, 
and ranged from 18 to 68%, indicating moderate to very severe airflow obstruction. 
Furthermore, the study group showed hyperinflation and reduced lung diffusion 
capacity.
Physiological responses
Mean duration of control exercise and exercise with NIV was similar, both 12.9 ± 2.8min. 
Baseline physiological values were not significantly different between both exercise 
conditions. Table 2 shows the physiological responses to both modes of exercise. Heart
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rate increased during exercise (p<0.05), but did not reach maximal predicted values. 
The heart rate responses to the different exercise modes were comparable. Although 
patients did not became hypoxemic during exercise, arterial oxygen pressures reduced 
significantly in response to both exercise modes. The decrease in arterial oxygen 
pressure was more after exercise with NIV-support than after control exercise (p<0.05). 
Arterial carbon dioxide pressures increased significantly during both control and NIV- 
supported exercise without a significant interaction-effect. Blood lactate levels, as well 
as sensation of dyspnea and leg discomfort, increased significantly after both exercise 
modes without any differences between the two exercise modes.
Table 1. Patient characteristics.
N 8
Gender (M/F) 4/4
A ge  (yrs) 62 ± 2
BMI (kg/m2) 23.1 ± 0 .9
FFMI (kg/m 2) (M/F) 14.7 ± 0 .8/  14.7 ± 0 .3
Pulmonary function
FEV1 (L) 1.12 ± 0.14
FEV1 (%pred) 42 ± 6
FEV1 /FVC (%) 33 ± 4
FRC (%pred) 142 ± 12
RV (%pred) 144 ± 12
TLC (%pred) 11 7 ± 6
DLCO (%pred) 45 ± 5
Pimax (%pred) 102 ± 10
Data are presented as mean ± SE. BMI: body mass index, DLCO: diffusing capacity for carbon 
monoxide, FEV1: forced expiratory volume in 1s, FRC: functional residual capacity, FVC: forced 
vital capacity, RV: residual volume, TLC: total lung capacity, Pimax: maximal inspiratory mouth 
pressure.
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Table 2. Physiological responses of control and NIV-supported cycle tests.
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Control NIV
Pre-exercise Response to 
exercise (A)
Pre-exercise Response to 
exercise (A)
Heart rate 
(beats/min)
78 ± 5 + 41 ±  4 a 74 ± 2 + 41 ±  6 a
Pa02 (kPa) 9 .6  ± 0 .5 - 0 .5  ±  0 .3 a 10.0 ± 0 .5 -1 .2  ±  0 .3 a ,b
PaC02 (kPa) 5.1 ± 0 .2 + 0 .5  ±  0.1 a 5 .2  ± 0 .1 + 0 .9  ± 0 .1 a
Lactate (mmol/L) 1.3 ± 0 .2 + 2 .4  ±  0 .7 a 1.1 ± 0 .1 + 2 .2  ± 0 .6 a
Dyspnea (Borg units) 0.9  ± 0 .3 + 3 .6  ±  0 .7 a 1.0 ±  0 .3 + 4 .8  ± 1 .1a
Leg discomfort 
(Borg units)
0 .4  ± 0 .2 + 2.9 ±  0 .8 a 0 .6  ± 0 .3 + 1.6 ± 0 .6 a
Data are presented as mean ± SE. A: max-rest, NIV: non-invasive ventilation, PaCO2: arterial carbon 
dioxide tension, PaO2: arterial oxygen tension.
a: exercise effect p<0.05, b: response is different than upon control exercise p<0.05.
Systemic inflammatory and oxidative stress responses
Absolute values at rest and the responses to both exercise modes are presented in 
Table 3 and 4. Baseline values of systemic inflammation and oxidative stress were not 
significantly different between both pre-exercise states.
IL-6 plasma levels increased significantly in response to control exercise, while IL-6 
levels did not rise upon exercise supported with NIV (Table 3). Accordingly, the IL-6 
response to NIV-supported exercise was significantly different from the response to 
control exercise (i.e. an interaction-effect, p<0.05). The different response to control 
exercise and NIV-supported exercise is also illustrated by Figure 1, in which IL-6 plasma 
levels upon exercise are expressed as relative changes from rest. IL-6 plasma levels 
increased by ~25% upon control exercise, while IL-6 plasma levels after NIV-supported 
exercise were only ~9% higher than at rest. Leukocyte plasma concentrations after 
control and NIV-supported exercise were significantly higher than at rest (Table 3). 
The leukocyte response to NIV-supported exercise was not significantly different from 
the response to control exercise. Likewise, neutrophil plasma levels also increased 
significantly and similarly in response to both exercise conditions (Table 3). Also when 
expressed as relative changes from rest, the leukocyte and neutrophil responses to 
both exercise modes were similar (Figure 2A and B). Neither control exercise nor NIV- 
supported exercise affected the plasma levels of CRP (Table 3).
The capacity of whole blood to produce ROS, a marker of oxidant production, was 
unaffected by exercise (Table 4). Accordingly, the plasma levels of carbonylated
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proteins, a footprint of oxidative stress, were neither affected by control exercise nor 
by NIV-supported exercise (Table 4).
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Table 3. Systemic inflammatory response to control and NIV-supported exercise.
Data are presented as mean ± SE. CRP: C-reactive protein, A: max-rest, NIV: non-invasive ventilation. 
a: exercise effect p<0.05, b: response is different than upon control exercise p<0.05.
Table 4. Oxidative stress response to control and NIV-supported exercise.
Data are presented as mean ± SE. A: max-rest, NIV: non-invasive ventilation, RLU: relative light 
units, ROS: reactive oxygen species.
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Figure 1. The relative responses from rest o f IL-6 plasma levels to control and NIV-supported 
exercise. NIV: non-invasive ventilation.
#: p<0.05.
Figure 2. The relative responses from rest o f leukocytes (A) and neutrophils (B) plasma levels to 
control and NIV-supported exercise. NIV: non-invasive ventilation.
DISCUSSION
The main finding of the current study is that NIV-support abolishes the IL-6 response 
to exercise in muscle-wasted patients with COPD. Yet, while NIV-support prevents 
IL-6 levels to rise, plasma leukocyte and neutrophil concentrations still increase upon 
exercise. So, NIV-support during exercise in these patients is not associated with a 
complete attenuation of the inflammatory response to exercise. Because NIV is known 
to specifically unload the respiratory muscles, the results from the present study provide 
additional insight into the mechanism of the inflammatory response to exercise in 
COPD. Furthermore, as NIV-supported exercise is increasingly being applied in research
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as well as rehabilitation settings, the current findings are relevant to consider when 
assessing clinical outcomes of NIV during exercise.
Systemic inflammatory and oxidative stress responses
The systemic inflammatory response to exercise has been extensively investigated, both 
in health and disease. The most pronounced marker of this response is IL-6.24 Compared 
to healthy individuals, the IL-6 response to exercise is higher in patients with COPD, 
in particular after submaximal exercise.13 In keeping with previous data, the current 
study shows that exercise at a submaximal level of 40W engenders a significant rise 
of plasma IL-6 levels in muscle-wasted patients with COPD. Because investigations 
in healthy subjects made clear that contracting skeletal muscle is the main source of 
circulating IL-6 in response to exercise,25 IL-6 is frequently referred to as a myokine. 
Interestingly, the amount of IL-6 release from muscle seems to depend on exercise 
intensity.26 In that respect however, it seems paradoxical, that COPD patients show a 
higher IL-6 response at much lower workloads compared to healthy subjects.13 Findings 
from the current study provide an explanation for this apparent contradiction. By 
applying NIV, the respiratory muscles were unloaded and the IL-6 response to exercise 
was almost completely abolished. Because the load on the peripheral muscles was 
identical between the two exercise modes, i.e. 40W, these data suggest that the main 
origin of IL-6 in COPD patients during submaximal exercise are not the peripheral 
muscles, but the respiratory muscles. This concept is supported by several previous 
observations. For example, Mercken and coworkers showed that localized leg muscle 
exercise of COPD patients did not result in elevated plasma IL-6 levels.27 Furthermore, 
Vassilakopoulos et al. demonstrated that increasing the load on the inspiratory muscles 
in healthy individuals leads to elevated IL-6 concentrations in plasma.28 The load on the 
respiratory muscles during exercise is excessively increased in COPD patients compared 
to healthy subjects.8 So, the supranormal IL-6 response to exercise observed in COPD 
patients could be explained by an increased IL-6 release from the respiratory muscles. 
In contrast to IL-6, NIV-support could not prevent the rise of leukocytes and neutrophils 
in response to exercise. The extra amounts of circulating leukocytes that appear 
upon exercise probably arise from an increased blood flow through lymphoid tissue, 
the non-circulatory leukocyte pool. Increased heart rate and vasomotor tone as a 
response to stress hormones during exercise are thought to lead to the release of extra 
leukocytes into the circulation.29 In the current study we did not measure the effect 
of NIV on for example catecholamines, but we did show that NIV had no effect on 
the heart rate response to exercise. This could explain why the increase of leukocyte 
concentrations was not affected by NIV-support. Although the main objective of the 
current study was to investigate the effect of NIV on markers of systemic inflammation, 
we additionally examined some markers of oxidative stress because oxidative stress 
and systemic inflammation have often been linked.16 For example, it is well known that
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leukocytes and in particular neutrophils are able to produce ROS under conditions of 
stress.30 As ROS modify the structure and function of proteins, fatty acids and genetic 
material, their presence in the circulation has been proposed to be harmful. In our 
study, we found no effect of exercise on the capacity of blood samples to produce ROS. 
In line with that, the plasma level of carbonylated proteins, a footprint of oxidative 
protein damage, were not elevated upon submaximal exercise. This is in contrast 
with previous studies from our lab, which did show an oxidative stress response to 
submaximal exercise in muscle-wasted COPD patients.618 The discrepancy between the 
current study and those previous studies can probably be explained by a lower level 
of muscle wasting in the patients that were currently studied. Accordingly, we have 
previously indeed demonstrated that the magnitude of the oxidative stress response is 
closely related to the severity of muscle wasting.6
Clinical implications
The current finding that NIV-support during submaximal exercise in COPD patients 
abolishes the IL-6 response, may have clinical implications. For example, high IL-6 
levels in patients with COPD are often related to detrimental systemic effects, such as 
skeletal muscle weakness,31 insulin resistance,32 exacerbations,33 and the development 
of comorbidities.34 Although a cause-effect relation of IL-6 and these systemic 
manifestations has never been determined in humans, it is noteworthy to mention 
that IL-6 overexpression and IL-6 infusion in rodents leads to airway inflammation,35 
skeletal muscle wasting,36 and myocardial failure.37 Therefore, it appears that 
depression of high IL-6 levels in patients with COPD is an attractive treatment. On 
the other hand however, several recent studies point to a functional role for IL-6 in 
response to exercise. For example, IL-6 facilitates glucose metabolism during exercise.26 
Furthermore, IL-6 may induce an anti-inflammatory environment following exercise 
by inhibiting the expression of the pro-inflammatory cytokine TNF-alpha and by 
stimulating the production of anti-inflammatory cytokines, such as IL-1 receptor 
antagonist and IL-10. We do therefore not exclude that the depressed IL-6 response 
during NIV-supported exercise affects glucose metabolism and favors the presence of 
an inflammatory environment. So, considering the complex physiological function of 
IL-6, it is obvious that intervention with NIV during exercise in COPD could have major 
clinical implications. Yet, whether these implications are favorable or harmful to the 
condition of the COPD patient is currently unclear and should be addressed in future 
studies.
Study limitations
We acknowledge that the set-up of the current study partially limits the interpretation 
of our data. First, although NIV is generally being applied to unload the respiratory 
muscles, we did not establish whether the load on the respiratory muscles was indeed
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reduced. As we wanted to resemble the clinical setting, we choose to adjust NIV-support 
according to patients comfort and not by an invasive evaluation of lung mechanics 
and respiratory muscle function. Nevertheless, similar approaches have been used in 
previous studies and showed to be effective in unloading the respiratory muscles.20,38 
Therefore we presume that NIV generally reduced the load on the respiratory muscles 
in the current study, but we also recognize that the NIV settings might not have been 
optimal for each patient. Remarkably, compared to control exercise, arterial oxygen 
pressure decreased more in response to NIV-supported exercise and arterial carbon 
dioxide pressures tended to increase more, suggesting that NIV reduced alveolar 
ventilation. Indeed, recent data from Hussain et al. show that NIV attenuated the 
increase in minute ventilation upon exercise while unloading the respiratory muscles 
in COPD patients at the same time.38 A second limitation of the study is that the results 
described in this study concern muscle-wasted COPD patients. As previous findings from 
our group have shown that the inflammatory response to exercise is more aggravated 
in muscle-wasted COPD patients than in non-muscle-wasted COPD patients,13 the 
current data cannot easily be extrapolated to non-muscle-wasted COPD patients. 
To that end, it is clinically important that future studies should address whether our 
findings also account for other subgroups of COPD.
Conclusion
In conclusion, the present study demonstrates that NIV abolishes the IL-6 response to 
submaximal exercise in muscle-wasted patients with COPD. These data suggest that 
the respiratory muscles contribute to exercise-induced IL-6 release in these patients. 
Because IL-6 plays an important role in the development of comorbidities in COPD 
and in the normal physiological response to acute exercise as well, these effects of 
NIV should be taken into consideration when applying NIV-supported exercise in both 
research and rehabilitation settings.
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STATINS IN COPD - THEORETICAL REFLECTIONS
Ned Tijdschr Geneeskd 2010;154:A2196.
ABSTRACT
• Systemic inflammation is thought to play a role in the pathogenesis of chronic 
obstructive pulmonary disease (COPD) and the extrapulmonary manifestations of 
this, including cardiovascular diseases.
• Besides cholesterol-lowering effects, statins have anti-inflammatory effects, which 
could equally have a positive influence on cardiovascular morbidity and mortality.
• Therefore hypothetically, statins could also play a role in preventing COPD 
progression and the development of extrapulmonary symptoms associated with 
COPD.
• Statin use for COPD might have a favorable influence on the deterioration of lung 
function, frequency of exacerbations, exertion tolerance and mortality, but the 
evidence for this is weak.
• The question is whether these findings can be explained by anti-inflammatory 
characteristics and/or by cholesterol-lowering characteristics in patients with a 
recognized or undiagnosed cardiovascular disease.
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Other than smoking cessation, and in the case of hypoxic patients maintenance 
treatment with oxygen at home, there are few interventions for chronic obstructive 
pulmonary disease (COPD) patients with proven effects on mortality.12 The current 
drugs (inhalation medication) contribute to an improved lung function and quality 
of life as well as fewer exacerbations, but have no effect on the progression of the 
disease and mortality.34 The question therefore arises as to whether other treatments 
that could have a positive effect are available. There is increasing attention for the 
possible favorable effects of statins on COPD5 and in this article we discuss the available 
literature concerning this.
COPD and extrapulmonary manifestations
COPD is a disease with a significant morbidity and mortality. Besides the traditional 
pulmonary focus, increasing attention is being paid to the extrapulmonary 
manifestations of this disease. Weight loss, skeletal muscle dysfunction, cardiovascular 
diseases, depression and osteoporosis are examples of such symptoms that occur 
outside of the lungs.6 These symptoms are viewed independently of smoking status and 
glucocorticoid use.67 Patients with stable COPD often have a low degree of systemic 
inflammation6 that can be established with a well-known marker, high-sensitivity 
C-reactive protein (hsCRP). Systemic inflammation is thought to play a role in the 
pathogenesis of COPD and the extrapulmonary manifestations.8 A large, three-year, 
longitudinal study into the significance of different inflammatory markers, including 
hsCRP, for COPD progression is currently being carried out.9
Statins
Statins (hydroxy-methyl-glutaryl-co-enzym A (HMG-CoA)-reductase inhibitors) safely 
reduce the cardiovascular morbidity and mortality in patients with an elevated 
cholesterol concentration within the context of primary and secondary prevention 
of coronary heart diseases.1011 It has been suggested that besides cholesterol­
lowering effects, statins might have so-called pleiotropic, in other words cholesterol 
independent, effects (Figure 1).12 The two isoprenoids shown in the figure, farnesyl 
pyrophosphate and geranylgeranyl pyrophosphate, are involved in the post- 
translational modification of a wide range of proteins from the intracellular signal 
transduction process. The anti-inflammatory effects of statins have been demonstrated 
in both in vitro and animal studies, for example.12 In humans, it has also been shown 
that the use of statins not only reduces the cholesterol concentration but also that of 
hsCRP.13 The question is whether these effects are genuinely cholesterol independent,
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as previously discussed.14 In the much discussed JUPITER study (Justification for the Use 
of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) rosuvastatin use 
by apparently healthy subjects without hypercholesterolemia but with an elevated 
concentration of hsCRP lead to a reduction in cardiovascular events.13 Both the hsCRP 
and cholesterol concentrations decreased as well as the cardiovascular risk. It therefore 
remains unclear whether this risk reduction occurred due to the hsCRP decrease and/or 
the cholesterol decrease. Several recent articles have considered this issue.1516
Figure 1. Point o f action o f statins in cholesterol synthesis and indication o f the pleiotropic 
effects. HMG-CoA: hydroxymethylglutaryl coenzyme A.
Statins for COPD
Pathogenesis and progression of COPD
Several studies have evaluated the effect of statins on the development and progression 
of COPD in experimental animals and humans. In rats it has been demonstrated that 
simvastatin inhibits emphysema induced by cigarette smoking.17 Over a period of 16 
weeks, rats were exposed to the smoke from 10 cigarettes per day with or without 
simvastatin 5mg/kg administered once daily orally. The rats treated with simvastatin had 
significantly less parenchyma destruction, inflammation and pulmonary hypertension 
and than the untreated rats. A high-dose simvastatin therefore appears to have an 
inhibitory effect on the development of emphysema in previously healthy rats. The 
significance of this for humans is unclear.
In a retrospective study of humans, the sequential lung function tests for both 
obstructive and restrictive disrupted lung function of smokers and ex-smokers who 
had or had not used statins were compared.18 Primary outcome measures were annual
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decrease in forced expiratory one-second volume (FEV1) and forced vital capacity (FVC). 
In the statin group, the FEV1 and FVC decreased less than in the control group. For the 
subgroup with obstructive disrupted lung function (FEV1/FVC <70%; that fits COPD) 
the FEV1 in the statin group increased by 5 (SD: 207)ml per year and in the control 
group it decreased by 86 (SD: 168)ml per year. For the FVC this was an increase of 33 
(SD: 452)ml and a decrease of 150 (SD: 328)ml per year respectively. Unfortunately, for 
this obstructive subgroup, no figures were given for the decrease in FEV1/FVC and so 
we still do not know if statins had a genuine effect on COPD progression. The smaller 
decrease in FEV1 and FVC in the statin group could also be explained by positive effects 
on cardiovascular disorders and with that, an associated improvement in lung function. 
Heart failure can be associated with a restrictive lung function disorder ('small lungs') 
which develops due to pulmonary edema, cardiomegaly or pleural effusion. With 
this the FEV1 and FVC decrease by comparable amounts, in contrast to obstructive 
lung disorder in which the FEV1 decreases more than the FVC. Statins would therefore 
appear to reduce the decrease in FEV1 and FVC, although the mechanism underlying 
this is unknown.
COPD morbidity
A number of studies have examined the effect of statin use on COPD morbidity. 
Previously a correlation was found between systemic inflammation, peripheral muscle 
weakness and exertion tolerance in patients with COPD; therefore a randomized, 
double-blind, placebo-controlled study was performed into the effect of pravastatin 
on exertion tolerance and the correlation with hsCRP.19 COPD patients who received 
pravastatin for 6 months, had a greater exertion tolerance after this and their hsCRP 
value decreased -as equally the cholesterol value- compared to those who had 
received the placebo. The subjects with the highest hsCRP values at the start of the 
study exhibited the greatest decrease in these values. A larger decrease in hsCRP was 
correlated (albeit very weakly) with a larger increase in exertion capacity. No description 
of cardiovascular risk profiles was given and the lung function parameters remained 
the same in both groups. However, exertion tolerance is not strongly related to the 
lung function parameters. Effects on systemic manifestations of COPD, such as body 
composition or muscle strength, were also not investigated in this study. Therefore 
whether pravastatin has a genuine effect on COPD, or more precisely COPD-related 
exertion intolerance, remains unclear.
A retrospective cohort study carried out among patients with 'COPD' as the primary 
or secondary diagnosis on discharge, showed that patients who used a statin were 
readmitted less frequently in connection with an exacerbation during the follow-up 
period of 1 year than those who had not used a statin.20 Another retrospective study 
investigated the number of hospital admissions related to COPD and also found a 
decrease in the case of statin use21. In view of their retrospective nature and use of 
databases, these studies need to be interpreted with care.
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COPD mortality
A number of other retrospective studies have revealed a positive effect of statins 
on COPD-related mortality,21-24 independent of the cardiovascular risk profile.21 It is 
cautiously suggested that this effect on mortality could be associated with anti­
inflammatory characteristics of statins. However, in view of the frequent association 
between COPD and undiagnosed heart failure, often caused by ischemic heart disease,25 
this effect also be explained by an effect on the cardiovascular mortality.
Consequences
Studies to date suggest that statins have a positive influence on various outcomes for 
COPD, but the evidence is weak. The studies described, especially the retrospective 
ones, must be viewed as hypothesis generating. In order to demonstrate that statins 
have a genuine effect on COPD patients, prospective randomized trials will have to be 
carried out with clinically relevant outcomes such as deterioration of lung function, 
exacerbation frequency, body composition, muscle strength and exertion tolerance, 
and mortality. A number of studies are currently being performed into the effects of 
statins on COPD that measure, for example, the frequency and severity of exacerbations, 
inflammatory biomarkers such as hsCRP, and lung function (www.clinicaltrials. 
gov: NCT01061671, NCT00655993, NCT00929734, NCT00700921, NCT00680641). 
Furthermore, it is not known, and is also difficult to investigate in a clinical setting, if 
statins have direct effects on COPD (via anti-inflammatory effects) or if they have an 
effect on the frequently present cardiovascular comorbidities (via cholesterol lowering 
and/or anti-inflammatory effects) (Figure 2).
Figure 2. Schematic representation o f pathogenetic connections between COPD and the effects 
o f statins.
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COPD and cardiovascular diseases/heart failure frequently occur together and 
differentiating between them on the basis of clinical data is sometimes difficult.26 We 
therefore recommend that for patients with cardiovascular diseases, the requesting 
of lung function tests should be made as easy as possible. For patients with COPD, use 
can be made of natriuretic peptides determination and imaging techniques such as 
ultrasound examinations.26
Conclusion
The presence of COPD is not yet sufficient reason to initiate a treatment with statins. 
However, based on the theoretical considerations described in this article and potential 
prospective randomized studies, this might well change.
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HEART FAILURE AND COPD: PARTNERS IN CRIME?
Respirology 2010;15:895-901.
ABSTRACT
Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are both common 
diseases with major impact and seem to coexist more frequently than expected from 
their separate population prevalences. However, estimates of combined prevalence 
must be interpreted carefully because of imperfections and difficulties in assessment 
of both diseases. This review aims to highlight HF prevalence in patients with COPD 
and vice versa, with a critical analysis of studies performed. First, definition, diagnosis, 
and prevalence of COPD and of HF will be discussed. Subsequently, an overview of 
important studies concerning combined prevalence with their limitations will be 
presented. Finally, pathogenic mechanisms and diagnostic considerations in clinical 
practice will be discussed.
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Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are both common 
diseases with major impact.1,2 Moreover, HF and COPD seem to coexist more frequently 
than expected from their separate population prevalences. Assessment of COPD 
occurrence in HF populations and vice versa is mainly based on hospital discharge 
diagnoses and/or medication prescription data. These estimates of combined prevalence 
may be very inaccurate, however. In one study, by Rutten et al., HF occurrence in COPD 
patients was thoroughly investigated.3 In a general practitioner's population, both 
COPD and HF were diagnosed according to current definitions.3 Contrarily, concurrent 
COPD in HF patients seems not so thoroughly investigated. Therefore, data regarding 
simultaneous COPD and HF remain scarce and results must be interpreted carefully 
because of imperfections and difficulties in assessment of both diseases.
The prevalence of combined COPD and HF is difficult to determine, because 1) risk 
factors, symptoms and signs are overlapping;4 2) hyperinflation in COPD may prevent 
adequate echocardiographic assessment; and 3) obstructive lung function abnormalities, 
not to be confused with COPD, may be present in acute HF.5 Although the diagnoses 
are complex, COPD and HF need a different approach, and pharmacotherapy for 
COPD may interfere with HF (pharmacotherapy) and oppositely. Cardioselective betal- 
blockers are considered to be safe in COPD patients, but cardiovascular safety of beta2- 
agonists is disputable.67 Therefore, an optimal treatment regimen must be carefully 
determined to balance positive and negative treatment effects in patients with COPD 
and HF. Knowledge of chances of concurrent COPD and HF facilitates the decision on 
additional testing in daily practice.
This review aims to highlight HF prevalence in COPD patients, and vice versa, with 
a critical analysis of performed studies. First, definition, diagnosis and prevalence of 
COPD and of HF will be discussed separately. Subsequently, an overview of important 
studies concerning combined prevalence will be presented and limitations discussed. 
We will end with pathogenic mechanisms, diagnostic considerations in clinical practice 
and conclusions.
Definition, diagnosis and prevalence of COPD
In the latest American Thoracic Society/European Respiratory Society position paper, 
COPD is defined as a condition characterized by a not fully reversible airflow limitation, 
indicated by a post-bronchodilator forced expiratory lung volume in 1s (FEV1)/forced 
vital capacity (FVC) <70%.8 COPD is classified according to Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) criteria.9 Patients usually have symptoms of dyspnea, 
cough and/ or sputum production and a history of exposure to risk factors, mainly 
tobacco smoke.8,9
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Estimates of prevalence of COPD depend on diagnostic criteria and definitions used.10 
In addition, spirometric cut-off points have changed over time.11 Even since the latest 
guidelines, gender- and age specific cut-off points for FEV1/FVC instead of a fixed ratio 
are proposed and have shown essential different results.12 Also, other approaches 
have been used to assess COPD prevalence, for example self-reported diagnosis ('Has a 
doctor ever told you that you had chronic bronchitis/emphysema?').1 
From the described prevalence studies, we have seen that spirometric assessment 
resulted in higher prevalence numbers than self-reported diagnosis of COPD.111 
Furthermore, women do report to have COPD more often than men despite lower 
prevalence according to spirometry.1 The larger spirometry-determined, compared 
to self-reported, COPD prevalence might origin from irreversible airflow limitation 
associated with bronchiectasis, cystic fibrosis and fibrosis due to tuberculosis.8 
Furthermore, discrimination between asthma and COPD can be difficult and additional 
tests might be required.1314 On the other hand, patients with a clinical diagnosis of 
COPD were found to have COPD according to pulmonary function tests in only 61% 
(general practice) and 71% (tertiary care).3,15 Also, underpresentation, underdiagnosis 
or misclassification may play a role.14 Clearly, spirometry is essential for COPD diagnosis. 
Although, even in a tertiary care setting, spirometry was performed in only 31% of 
COPD patients over the past eight years.15 For prevalence purposes, self-reported 
diagnosis is more often used than spirometry, probably because of time and financial 
limitations.
Worldwide prevalence of COPD according to the current spirometric definition 
ranges from 7.8-26.1% (Table S1 in the online supporting information) and is higher 
with increasing age, in smokers and in men, although prevalence in women is 
increasing.1,11,16,17
Definition, diagnosis and prevalence o f chronic heart failure
Many different definitions of HF have been used in the past. According to the most 
recent guidelines, HF is a complex clinical syndrome with symptoms and signs typical 
of heart failure and objective evidence of a structural or functional abnormality of 
the heart at rest (physical examination, echocardiography or natriuretic peptide 
concentration).1819 Typical symptoms are dyspnea, fatigue and typical signs are rales 
and oedema.18,19 There is no single diagnostic test, although the most useful diagnostic 
test in the evaluation of patients with HF is the comprehensive two-dimensional 
echocardiogram together with Doppler flow studies.18
Although many disorders may result in HF, main causes are coronary artery disease 
and hypertension.20 Various descriptive terms of HF are used, for example systolic and 
diastolic HF.19 More recently, instead of systolic and diastolic HF, HF with reduced and 
normal left ventricular ejection fraction (LVEF) is preferred, since diastolic dysfunction
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occurs in diastolic HF as much as in systolic HF.21,22 Whether these two are ends of 
the spectrum or two distinct syndromes is still matter of debate.22 Although HF with 
reduced LVEF has been studied mostly, about half of all patients with HF have normal 
LVEF.21,22 Anyhow, prevalence of HF also depends on diagnostic criteria and definition, 
and ranges from 2.2-3.9% (Table S2 in the online supporting information). Also, 
prevalence increases with increasing age.2 23 24
Left ventricular dysfunction is objective evidence of cardiac dysfunction and not 
necessarily HF. Whether these abnormalities are preclinical or patients adapt their 
activities to their symptoms and do not experience them, or do not go to a doctor 
is unclear. Left ventricular systolic dysfunction (LVSD) is generally defined as LVEF 
<40-50%, although there is no consensus concerning the cut-off.19 LVSD prevalence 
ranges from 2.0-7.7% with different cut-off points for LVEF.2 23 24 In contrast to the 
relatively straightforward method to diagnose LVSD, many different parameters are 
used to describe left ventricular diastolic dysfunction (LVDD) and criteria have changed 
recently.22 25 According to the most recent criteria, LVDD is indicated by LVEF >50% 
and left ventricular end-diastolic volume index <97ml/m2, plus invasively measured 
left ventricular end-diastolic pressure >16mmHg, or mean pulmonary capillary wedge 
pressure >12mmHg, or time constant of left ventricular relaxation >48ms, or constant 
of left ventricular chamber stiffness >0.27; or plus tissue Doppler determined E/E' >15 
(E: early mitral valve flow velocity; E': early diastolic lengthening velocity of mitral 
annulus).22 When 15 >E/E'> 8, additional echo (Doppler), blood or electrocardiographic 
investigations are necessary to prove diastolic dysfunction.22 Described prevalences of 
mild, moderate, and severe LVDD are respectively 20.8, 6.6 and 0.7%.24
Prevalence of heart failure in COPD
Heart failure in stable COPD
In a cross-sectional study in elderly COPD patients from general practice, prevalence 
of unrecognized HF turned out to be 21%.3 Patients were subjected to a diagnostic 
work-up including questionnaires, physical examination, chest radiography, electro- 
and echocardiography and pulmonary function tests. COPD was confirmed according 
to the GOLD criteria. An expert panel decided about the existence of HF using all 
available diagnostic information. Half had systolic, half isolated diastolic and none 
right-sided HF. Age and smoking history were similar, but a history of ischaemic 
heart disease, hypertension or diabetes mellitus was more frequently seen in COPD 
patients with concurrent HF compared to those without. Because signs and symptoms 
between these groups were comparable, patients with asymptomatic left ventricular 
dysfunction might have been included in the HF group. As this study was performed in 
general practice, conclusions regarding other populations cannot be drawn.
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Heart failure in COPD exacerbations
Patients with a history of asthma or COPD (self-report and medical record) and without 
a history of HF presenting to the emergency department with acute dyspnea were 
evaluated for HF.26 In 21%, congestive HF was diagnosed after discharge by two 
independent cardiologists using all obtainable information (blinded for natriuretic 
peptide levels).26 The group with HF was older than the group without (71 versus 
60 years). In patients with HF, a history of coronary heart disease, atrial fibrillation 
and diabetes mellitus was more common than in those without. Unfortunately, no 
smoking data were presented. Some severe limitations of this study need to be taken 
into consideration. Namely, no distinction between asthma and COPD was made, and 
no spirometry was performed to verify the diagnoses. Furthermore, echocardiography 
was performed in only 29% of the study population.
In another study, patients admitted for a severe acute exacerbation of their COPD 
without obvious cause were studied by an expert panel.27 In 51%, echocardiographic 
left ventricular dysfunction was found, of which 64% was systolic, 23% diastolic 
and 13% both. After discharge, an expert panel could confirm in 31% of the acute 
exacerbations a definite association with left ventricular dysfunction. The limitation of 
this study was that COPD was not validated by pulmonary function testing.
Heart failure hospitalization in COPD
In database studies, hospitalization for congestive HF was reported to be approximately 
three times higher in COPD patients compared with matched controls (Table S3 in the 
online supporting information).28'30 COPD and HF were assessed by discharge diagnoses 
and/or medication prescriptions, which might be very inaccurate to make a diagnosis. 
Furthermore, it might be that patients with COPD and HF are more often hospitalized 
for HF than those with HF but without COPD.
Left ventricular dysfunction in COPD
The prevalence of LVSD was reviewed in COPD patients without overt coronary artery 
disease and hypertension and varied from 0-16% (5 out of 8 studies found a prevalence 
of 0%).31 When LVSD was found, it was generally mild and mainly in patients with a 
history of cor pulmonale. In patients with a COPD exacerbation, prevalence varied 
from 0-32%.31 In groups without exclusion of patients with cardiovascular disease, 
LVSD varied from 10-46%.31 Surprisingly, the lowest prevalence was reported in COPD 
patients with clinically suspected left ventricular dysfunction.32 In summary, LVEF seems 
to be normal in COPD patients without recognized cardiovascular co-morbidity (Table 
S4 in the online supporting information).32-38 In those with an affected right heart, 
generally lower but still normal ejection fractions were found.33 35 37 38 
In a large cohort of stable emphysema patients without a history of cardiovascular 
disease, mean pulmonary capillary wedge pressure was 14mmHg,36 indicating mild
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LVDD. Some smaller studies showed no LVDD in comparable patients (Table S5 in 
the online supporting information).333739 Boussuges et al. compared clinically stable 
patients with severe COPD and without a history of hypertension or heart disease with 
healthy subjects.40 They found a correlation between left atrium and left ventricular 
filling pattern on the one hand and right ventricle pressure and diameter on the 
other hand, so-called ventricular interdependence, which has been described earlier.41 
Comparable findings were observed by others, especially in patients with elevated 
pulmonary artery pressure (Table S5 in the online supporting information).42 43 LVDD 
during COPD exacerbation ranged from 0-41%.44-46
Instead of discriminating between LVSD and LVDD, a myocardial performance index 
((isovolumetric contraction time + isovolumetric relaxation time)/ejection time) was 
used as an index of global ventricular function in non-cardiovascular affected COPD 
subjects. Left ventricular myocardial performance index was increased in patients 
with COPD and pulmonary hypertension compared to those without pulmonary 
hypertension and to controls.38
Prevalence of COPD in heart failure
COPD prevalence according to GOLD criteria of 39% was reported in HF patients with 
reduced LVEF.47 Initial assessment in an outpatient HF clinic included spirometry with 
reversibility testing, and retrospectively COPD prevalence was determined.47 Although 
patients were reported to be stable, it is questionable whether patients were optimally 
treated at initial assessment. Because obstructive lung function abnormalities may be 
present in acute HF and may disappear with treatment,5 this might have influenced 
their reported COPD prevalence.
A very recent review showed a prevalence of COPD in HF hospitalization populations 
of 9-51% and in stable outpatients of 7-13%, with diagnoses based on disease codes 
and medication use,48 which may be imprecise, as stated before.
Pulmonary function disorders in heart failure
To assess the effects of HF on spirometry, pulmonary function was assessed serially 
during a mean follow-up of 310 days in 28 patients with acute HF, without a history of 
COPD.5 As expected, a restrictive, but also an obstructive lung function disorder with 
a mean prebronchodilatory FEV1/FVC of 66% was found initially. After the treatment 
of HF, this ratio improved to normal only in non-smokers (smokers mean FEV1/FVC 
64%, but in 5 of the 13 smokers >70%). The persisting obstruction in smokers after 
treatment of HF might be due to undiagnosed COPD or asthma. In this study, it is not 
clear whether non-smokers had a smoking history. Also, reversibility was only tested 
in 64% of the subjects and in these patients no reversibility was found. The persisting 
obstruction in smokers after treatment of HF might be due to undiagnosed COPD or 
asthma.
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Similarly, hospitalized patients with severe HF showed FEV1/FVC ratios (without 
reversibility testing) before and after HF treatment of 63 and 78% respectively.49 
Furthermore, flow limitation (measured by negative expiratory pressure), especially 
in supine position, has been demonstrated in acute HF patients.50,51 This was shown 
to disappear after treatment with diuretics and vasodilators.51 It is suggested that 
this flow limitation is caused by airway obstruction due to intrathoracal blood shift 
with compression of peripheral airways by the distended pulmonary arteries.5,51 
Subsequently, interstitial oedema is thought to develop and ultimately alveolar 
oedema.5
In stable congestive HF patients without a history of COPD or asthma, no obstruction 
was demonstrated, although some found large standard deviations (FEV1/FVC 73-80 ± 
7-20%).52'54 After bronchodilation, FEV1/FVC improved from 80 ± 7 to 83 ± 6% in non­
smokers and from 75 ± 11 to 77 ± 9% in smokers with severe congestive HF (Table S6 
in the online supporting information).53
The conclusion from the presented studies might be that HF may cause an obstructive 
pulmonary function pattern in the acute phase, disappearing with treatment of HF.
Shortcomings of studies concerning simultaneous COPD and heart failure
Substantial variation in prevalence of concurrent HF and COPD is reported and this 
seems to have several reasons. Different definitions have been applied, for example 
based on objective measurements, self-report or drug exposure. In case of objective 
measurements, the two conditions were usually defined according to established 
criteria; however, they have changed over time. Furthermore, on the basis of a single 
lung function measurement, it is impossible to discriminate between asthma and 
COPD. Also, left ventricular function has been assessed by different techniques, such 
as catheterization, echocardiography and radionuclide ventriculography, and different 
cut-off points have been applied. Additionally, a considerable number of patients have 
been excluded in several studies because of poor echogenicity due to hyperinflation. 
Finally, patients with varying disease severity and, in case of COPD, with and without 
concomitant cardiovascular diseases have been studied. Conclusions are therefore 
hard to draw. To elucidate prevalence of HF in COPD and vice versa, prospective studies 
should be performed.
Pathogenic mechanisms of concurrent COPD and heart failure
Apart from smoking as a common risk factor, COPD patients are suggested to have 
an additional cardiovascular risk factor.55 56 Like cardiovascular diseases, stable COPD 
is associated with low-grade systemic inflammation.57 58 Sin and Man analyzed the 
relation between COPD, systemic inflammation and cardiovascular disease.59 Risk of
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underlying ischaemic heart disease was greatest in patients with moderate or severe 
airflow obstruction and highly elevated C-reactive protein, suggesting an additional 
effect of this inflammatory marker on cardiac risk. Furthermore, several markers of 
cardiovascular risk are associated with airflow limitation.60-62 In addition, C-reactive 
protein concentrations were found to be correlated with vascular structure and 
function in COPD patients,60,63,64 although not consistently.65 Cardiovascular diseases 
in turn are the main cause of HF.20 On the other hand, pulmonary hypertension is 
common in severe COPD66 and finally leads to right HF.67 Right HF in turn is associated 
with left HF.40'41 In summary, COPD patients seem to be at higher risk for cardiovascular 
disease, including HF, caused by the same pathogenic mechanism.
Diagnostic considerations in clinical practice
In patients with COPD, plasma levels of natriuretic peptides, simple and relatively 
cheap diagnostic tests, can be useful. In stable elderly COPD patients in a primary care 
setting, optimal cut-off values of 35pg/ml for B-type natriuretic peptide (BNP) and 
of 125pg/ml for aminoterminal-proBNP (NT-proBNP) were found with sensitivities of 
71% and 78% and specificities of 58% and 58%, respectively68. Therefore, these tests 
perform better in excluding than detecting HF. For detecting HF in stable COPD patients 
imaging techniques appear more suitable.4 Different cut-off values apply to COPD 
patients with acute dyspnea. Cut-off values of BNP and NT-proBNP derived from large 
studies in patients presenting with acute dyspnea to the emergency department6970 
were tested in a subgroup of patients with a history of COPD.2671 A single cut point for 
BNP to exclude/detect HF was </> 100pg/ml, with a sensitivity of 93% and a specificity 
of 77%26. Although not specifically tested in patients with a history of COPD, BNP 
>500pg/ml is suggested by others to indicate acute HF.4 However, they emphasized 
that it does not necessarily differentiate between a cardiac or pulmonary cause of 
clinical deterioration but indicates that HF therapy should be initiated, and cardiac 
imaging should be performed when stable.4 Finally, in COPD patients with BNP levels 
of 100-500pg/ml, cor pulmonale (right ventricular stretch) might be the source (or 
moderate LV failure).472 For NT-proBNP, a value of <300pg/ml to exclude HF, and of 
>450pg/ml for patients <50 years and >900pg/ml for those >50 years to detect HF was 
tested in patients with previous COPD presenting with acute dyspnea.71 For excluding 
HF sensitivity was 94% and for detecting HF specificity was 84%. In COPD patients 
with previous HF these values were 97% and 47%, respectively, and in those without 
previous HF 90% and 90%, respectively.71 When natriuretic peptides were added to 
clinical judgment, 95-100% of the patients were correctly diagnosed.2671 In a group 
admitted to the intensive care unit for severe exacerbation of COPD, much higher 
levels of NT-proBNP levels of <1000pg/ml to exclude (sensitivity 94%) and >2500pg/ 
ml to detect (specificity 86%) HF were found to be optimal.27 Thus, generally, values
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derived in patients with acute dyspnea are also applicable to patients with a history 
of COPD, and the combination of clinical judgment together with natriuretic peptides 
provides a good diagnostic framework. In case of doubt cardiac imaging techniques 
should be applied.
To investigate simultaneous COPD in stable HF patients, repeated spirometry with 
reversibility testing should be performed. In the acute situation, it might be impossible 
to perform reliable spirometry and concurrent COPD can only be determined after the 
acute phase.
Conclusion
Based on recent studies, COPD and HF seem to coexist more often than expected from 
its separate prevalences. However, reported numbers should be interpreted cautiously, 
because there are generally shortcomings according to definition and assessment 
of both diseases. LVSD does not seem to play an important role in COPD patients 
without concomitant cardiovascular disease, in contrast to LVDD, which is suggested 
to be mediated by ventricular interdependence. Future studies should be directed 
at determining more precise estimates of coexistence of COPD and HF and optimal 
diagnosis and treatment.
In clinical practice, there should be awareness of increased combined prevalence of 
COPD and HF. At least in patients with excessive symptoms despite optimal treatment, 
additional investigations should be performed.
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SUMMARY & GENERAL DISCUSSION
SUMMARY
According to the American Thoracic Society/European Respiratory Society, chronic 
obstructive pulmonary disease (COPD) is characterized by a progressive airflow 
limitation.1 Furthermore, COPD is associated with an abnormal inflammatory response 
of the lungs to noxious particles or gases, and has systemic consequences.1 In this 
thesis, we aimed to investigate clinically important consequences of these two aspects 
of COPD. First, we examined the consequence of airflow limitation on operating lung 
volumes during exertion. Second, we investigated and reviewed systemic consequences 
of COPD, like systemic inflammation and cardiovascular comorbidity.
Operating lung volumes in COPD
Operating lung volumes, like dynamic hyperinflation (DH) and inspiratory reserve 
volume (IRV), are commonly deduced from repeated measurements of inspiratory 
capacity (IC).2 The aim of chapter 2 was to test the validity of Oxycon Mobile, a 
mobile and wireless cardiopulmonary exercise testing device, to measure IC at rest 
and during steady-state exercise. The fixed cardiopulmonary testing device Oxycon Pro 
was considered as the golden standard. The limits of agreement of the IC measured 
by Oxycon Mobile and Oxycon Pro both at rest and during exercise were ±10%, which 
is recommended for interdevice reproducibility.3 We concluded that Oxycon Mobile 
and Oxycon Pro can be used interchangeably for measuring IC's and thus operating 
lung volumes. Therefore, Oxycon Mobile was used to determine DH and IRV during 
self-chosen dyspnea causing activities of daily living (ADL) at patients' homes, in 
chapter 3. In order to get better insight into causes of dyspnea and exercise limitation 
in real-life, DH and IRV were compared in COPD patients with different severities of 
airflow limitation, i.e. Global initiative for chronic Obstructive Lung Disease (GOLD) 
GOLD stage II-IV. ADL varied from vacuum cleaning and carrying bags to washing the 
dishes and walking. No significant difference in DH at end ADL was found between the 
GOLD categories, but it seemed less in GOLD IV. However, at isotime (2min) there was 
a tendency for increasing DH with increasing GOLD stage, which was again blunted 
in GOLD IV subjects. This was in accordance with our hypothesis that DH increases 
with increasing airflow obstruction, but that this flow limitation effect is blunted by 
a volume limitation in the patients with the most severe COPD. IRV at end ADL was 
not significantly different, but at isotime it was significantly smaller in the most severe 
groups. Only GOLD IV subjects reached the dyspnea limit (IRV ~0.5L).4 Although GOLD 
II and III subjects tended to develop more DH after ADL, they scored less dyspnea 
than GOLD IV subjects. They did not reach the dyspnea limit because of less static
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hyperinflation, supporting the idea that limited IRV is a more important determinant 
of dyspnea than DH. Activity limitation in the most severe group was probably a 
combination of reaching the dyspnea limit and minimal breathing reserve (<11L and/ 
or 15% of maximal voluntary ventilation, which is estimated by 37.5xforced expiratory 
volume in 1s (FEV1)).5 We concluded that DH occurred independent of disease severity 
in daily life. Furthermore, low IRV, which is determined by static plus dynamic 
hyperinflation, is a more important than DH for dyspnea and exercise limitation, and 
decreases with increasing airflow obstruction.
In contrast to most laboratory settings, where ergometry and walking are the most 
frequently used exercise activities, ADL include arm effort. Interestingly, more dyspnea 
is reported during arm than during leg exercise.6 As DH is an import contributor to 
dyspnea,4 the study in chapter 4 compared the amount of DH between arm and 
leg steady-state exercise. To exclude the effect of ventilation, DH was measured at 
equal ventilation (isoventilation). It was hypothesized that DH is greater during arm 
exercise, mainly because of greater dependence on breathing frequency to increase 
ventilation. Thoracic muscle use for arm positioning and posture may lead to a stiffer 
thorax, which makes it more difficult to expand tidal volume and may lead to a greater 
dependence on breathing frequency. In contrast to this hypothesis, the level of DH 
was not significantly different, despite a greater dependence on breathing frequency 
during arm exercise. Steady-state IRV was significantly greater for arm exercise due to 
a smaller tidal volume. However, during neither kind of exercise the critical limit of 
~0.5L for IRV was reached. Accordingly, we did not find greater breathing discomfort 
during arm exercise at isoventilation. From this study, we concluded that equal DH 
developed during arm and leg ergometry at isoventilation in patients with COPD, 
despite a greater dependence on breathing frequency with consequent less expiratory 
time during arm exercise. However, it could be that the difference in frequency was 
too small to exert its effect on DH, or that small differences of DH were not detected. 
Previous studies show that changes in operating lung volumes are better predictors 
of patient-centered outcomes than FEV178 Yet, in contrast to the decline in FEV1, it is 
unknown how DH develops during the disease course. Therefore, the aim of chapter 
5 was to investigate DH during a two year follow-up in patients with COPD. DH was 
induced by metronome paced hyperventilation (MPH), a simple applicable surrogate 
for exercise to detect DH.9 In patients with mild-to-severe COPD, we found an increase 
in DH of 0.23L during two years of follow-up, without a change in FEV1 %pred. Smokers 
showed a more rapid decline in FEV1 and a higher increase of DH during two years than 
non-smokers, whereas the change in static hyperinflation was similar. These results 
indicate that DH is a sensitive measure to track consequences of changes in airflow 
obstruction.
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Systemic effects in COPD
COPD is associated with low-grade systemic inflammation at rest,10 which has 
been related to the development of systemic comorbidities, such as cardiovascular 
disease and muscle wasting.11'15 Furthermore, different kinds of exercise lead to an 
inflammatory response in (muscle-wasted) COPD patients.1617 The aim of chapter 6 
was to investigate whether non-invasive ventilation (NIV) could blunt the systemic 
inflammatory response to exercise compared to control exercise. NIV generally 
results in greater exercise tolerance and less dyspnea18 by unloading the respiratory 
muscles.1920 We hypothesized that the inflammatory response to exercise in patients 
with COPD could be suppressed by the appliance of NIV. The main finding of the study 
was that NIV abolished the IL-6 response to exercise in muscle-wasted patients with 
COPD. Yet, while NIV-support prevented IL-6 levels to rise, this was not associated with 
a complete attenuation of the inflammatory response to exercise. Since NIV is known 
to specifically unload the respiratory muscles, these data suggest that the respiratory 
muscles contribute to exercise-induced IL-6 release in these patients. Because IL-6 
plays an important role in the development of comorbidities in COPD21 and in the 
normal physiological response to acute exercise as well,22 these effects of NIV should 
be taken into consideration when applying NIV-supported exercise in both research 
and rehabilitation settings.
Other interventions related to systemic inflammation are statins. Preliminary data show 
positive effects of statins in COPD, which were reviewed in chapter 7. Statins safely 
reduce cardiovascular morbidity and mortality in patients with elevated cholesterol for 
primary and secondary prevention of coronary heart disease.2324 Next to cholesterol­
lowering effects, so-called pleitropic or cholesterol-independent effects are suggested. 
Promising effects of statins in COPD have been described on development and 
progression of COPD, morbidity and mortality. However, to conclusively evaluate the 
effects of statins in COPD, prospective, randomized trials with relevant endpoints, like 
lung function decline, exacerbation frequency, body composition, muscle force and 
exercise tolerance have to be performed.
Cardiovascular disease and heart failure (HF) are examples of comorbidities of COPD. 
In chapter 8, we reviewed the prevalence of combined COPD and HF. Determining the 
prevalence of coexisting COPD en HF is complex for several reasons. First, overlapping 
risk factors, symptoms and signs complicate HF diagnostics in COPD and vice versa. 
Furthermore, since diagnosis of both diseases is relatively time-consuming, hospital 
discharge diagnoses and/or medication prescription data are often used to determine 
combined prevalence. Finally, changes in definitions of both diseases occurred. The 
prevalence of HF was investigated in COPD according to the current definitions and 
turned out to be 21%.25 In contrast, concurrent COPD in HF patients seems not so 
thoroughly investigated and prevalence based on databases ranges from 7 to 51%.26
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Left ventricular systolic dysfunction does not seem to play an important role in COPD 
patients without concomitant cardiovascular disease in contrast to left ventricular 
diastolic dysfunction.27 Left ventricular diastolic dysfunction is suggested to be mediated 
by elevated pulmonary vascular resistance and consequent leftward shift of the septum,
i.e. ventricular interdependence.2829 Increase in pulmonary vascular resistance may 
occur as a result of various mechanisms, including loss of pulmonary vascular capacity 
due to parenchymal destruction, hypoxic pulmonary arterial vasoconstriction, and 
pulmonary hyperinflation.3031 In unselected (concomitant cardiovascular disease not 
excluded) patients with COPD, cardiovascular disease may be an additional mechanism 
for the increased simultaneous prevalence of COPD and (systolic and diastolic) left 
ventricular dysfunction/HF.32 Future studies should be directed at optimal diagnosis 
and treatment in patients with concurrent COPD and HF.
GENERAL DISCUSSION 
Operating lung volumes in COPD
The data from the first part of this thesis provide more insight into the development of 
DH and a decreased IRV. Theoretically, the occurrence and amount of DH depend on: 
(1) the severity of airflow limitation, (2) the level of ventilation, (3) breathing pattern, 
and (4) the amount of static hyperinflation.
In contrast to this model, the study described in chapter 3 did not show a difference in 
the amount of DH between patients with different degrees of airflow obstruction. This 
observation was confirmed in a follow-up study (chapter 5), which showed, only in the 
smokers subgroup, a weak correlation between FEV1 and DH. This discrepancy might 
be explained by the fact that FEV1 does not represent total airflow limitation, because 
it does not incorporate the smaller airways. Therefore, it would be interesting to study 
whether DH correlates with additional parameters of airflow obstruction that better 
describe total airflow limitation, like measures of peripheral obstruction or airflow 
limitation assessed by the negative expiratory pressure technique or forced oscillation 
technique.3334 Very recently, a new method has been introduced to determine airflow 
limitation during exercise by quantifying the concavity of the spontaneous expiratory 
flow-volume curve, but this method first needs to be validated.35 
With respect to the dependency of DH on ventilation, it is important to note that 
COPD patients increase their ventilation during exercise mainly by increasing breathing 
frequency. Consequently, time for expiration reduces. As airflow is typically limited in 
COPD, this shorter expiratory time leads to DH. We did not investigate the effect of 
different levels of ventilation on DH. However, in chapter 3, ventilation was different 
between the GOLD categories, and therefore the rate of DH (change in IC per change 
in ventilation) was determined afterwards (data not shown). No differences in this
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rate were found between the GOLD stages at end ADL and at isotime. However, this 
type of exercise may not be appropriate for investigating the effect of ventilation on 
DH. For adequate determination of this effect, repeated IC measurements during a 
standardized incremental test or during tests with different steady-state ventilation 
levels are needed.
A previous study compared four constant work rate cycle tests (at 65, 75, 85 and 
95% of peak workload) and found that increased respiratory rates and decreased 
tidal volumes coincided with higher levels of DH.36 Other authors reported increased 
breathing frequency and a greater level of DH during constant work rate arm tests 
with increasing workloads (50, 65, 80% of peak), although tidal volume data were 
absent.37 It could be that the relation between ventilation and DH is only determined 
by the increase in breathing frequency and not by tidal volume, which could be subject 
of further research. In chapter 4, at isoventilation arm versus leg exercise, the effect 
of breathing frequency on the level of DH could not be confirmed, which could be 
explained by the small difference in frequency.
Finally, the amount of DH depends on the levels of static hyperinflation.38 Accordingly, 
the results from studies in chapters 3-5 show that patients with higher levels of 
static hyperinflation develop less DH. This could be explained by less room to further 
hyperinflate. Consequently, DH in these patients rapidly reduces IRV to values below 
0.5 L, i.e the dyspnea limit, stressing the importance of IRV.
In conclusion, as several factors contribute to DH, it is difficult to define specific groups 
that are sensitive and activities that lead to DH.
Relevant DH is currently defined as a decrease in resting IC of 0.5L post-bronchodilation, 
or 0.3L pre-bronchodilation.4 These values lead to a sharp increase in breathing 
discomfort, as did a common value of ~0.5L for IRV.4 Bronchodilation results in a 
greater resting IC4 and therefore less static hyperinflation, explaining the tolerance 
of a greater amount of DH post-bronchodilation but of equal IRV, assuming that total 
lung capacity (TLC) remains stable. Otherwise, any decrease in IC greater than 150ml 
or 10%,39 could be considered as DH. Furthermore, ratios, for example IC/TLC, have 
been used to express DH.239 However, in contrast to a reference value of IC/TLC at rest 
of 0.25,40’42 no cut-off points are known for relevant DH expressed as ICexercise/TLC. 
Similarly, it might be better to express IRV as a percentage decrease or as a percentage 
of TLC, but no reference data are available. Future studies could be directed at 
determining the best method to describe clinically relevant DH and minimal IRV.
The current thesis shows that DH and IRV are related to dyspnea and exercise 
intolerance, even during ADL. Previous studies have shown that DH after a symptom- 
limited incremental cycle test is the best predictor of decreased physical activity,43 
which in turn is related to reduced health-related quality of life in COPD.44 However, 
exercise intolerance in COPD does not only depend on operating lung volumes. Other 
factors, like reaching the minimal breathing reserve, hypercapnia, hypoxia, peripheral
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muscle dysfunction and competition between respiratory and locomotor muscles all 
together play a role in a complex interplay.54546 Also, non-physiological aspects, like 
anxiety, may contribute to exercise limitation.47 In mechanical studies concerning 
exercise constraints, non-physiological effects must be considered as well.
Several interventions have been suggested to improve exercise performance. Generally, 
bronchodilators have no effect on the level of d H,9 48 49 but improve static hyperinflation 
and exercise tolerance.4,50 Bronchodilators have also been shown to accelerate the 
dynamics of muscle oxygen delivery and utilization.51 Another measure to reduce 
dyspnea, increase exercise performance, and improve health-related quality of life is 
pulmonary rehabilitation.52 This multidisciplinary intervention is pointed at physical, 
psychological and social aspects of the disease. After rehabilitation and at similar work 
rate, DH has shown to be less than before rehabilitation.53 Furthermore, additional 
strategies as ventilation-feedback has been shown to result in less DH.54 Nutritional 
supplementation, polyunsatured fatty acids and anabolic steroids in addition to a 
rehabilitation program have been shown to improve exercise capacity compared to 
rehabilitation alone,55-57 but the effect on DH was not assessed. Furthermore, Heliox 
(Helium-oxygen mixture; a low-density gas mixture; lowering air way resistance 
and thereby increasing flow and ventilation) and oxygen (lowering the ventilatory 
demand) resulted in improved exercise capacity and less DH.58'61 In selected patient 
groups, lung volume reduction surgery leads to increased exercise tolerance and 
decreased DH.62 Other measures that may ultimately improve exercise tolerance could 
be pharmacological and nutritional interventions, which will be discussed in the next 
section.
Systemic effects in COPD
The data from the second part of this thesis concern systemic effects in COPD. It 
has generally been accepted that COPD is a complex disease, comprising more than 
airflow limitation alone. Beside the lungs, dysfunction of other organs may occur 
during the progression of COPD. For example, several studies have shown that HF is a 
common comorbidity in patients with COPD, as reviewed in chapter 8. However, the 
pathophysiological mechanisms underlying the coexistence of these two diseases are 
currently unclear. Interestingly, the main study object of the first part of this thesis, 
hyperinflation, may contribute to the development of HF in COPD. Hyperinflation has 
been shown to be associated with lower oxygen pulse, a measure for stroke volume, in 
patients with COPD.42 Different mechanisms for this phenomenon have been suggested. 
It has been proposed that increased intracardiac pressures caused by hyperinflation 
reduce venous return, and reduce stroke volume.3042 63 Others suggested that venous 
return (preload) increases by large negative deflections in intrathoracal pressure to 
overcome the inspiratory threshold load (due to DH), and by excessive use of the
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abdominal (expiratory) muscles (although this excessive use has also been suggested 
to act as a Valsalva maneuver to decrease venous return).6465 Furthermore, as a result 
of enhanced lung volume (and parenchymal destruction and hypoxia), increased 
pulmonary vascular resistance and right ventricular afterload occurs.64 Both increased 
right ventricular preload, leading to leftward shift of the septum, and increased 
right ventricular afterload result in a decreased left ventricular stroke volume.64 The 
common consequence of the suggested mechanisms is a decreased cardiac output due 
to (dynamic) hyperinflation.42 6466
Systemic manifestations, such as systemic inflammation, hypoxia, increased sympathetic 
activation, vascular dysfunction, connective tissue degradation and accelerated aging, 
are expected to contribute to the coexistence of COPD and cardiovascular disease.32 67 
Although the involvement of systemic inflammation has been investigated most 
extensively, results remain inconclusive. First of all, the origin of systemic inflammation 
is unclear and is probably multifactorial.11 It has for example been suggested that 
systemic inflammation is a spill-over of pulmonary inflammatory mediators into 
the circulation. On the other hand, pulmonary inflammation may just be part of a 
systemic inflammatory state with multiple organ compromise.68 In addition, systemic 
inflammation can arise from any comorbidity, with subsequent effects on the lung.1214 
Furthermore, distinction between a systemic manifestation of COPD and 'independent' 
comorbidity is difficult.12 Future research should elucidate the complex relationship 
between COPD, coexisting conditions, and systemic inflammation accompanying these 
different conditions.
Irrespective of its origin, low-grade systemic inflammation has been suggested to 
affect pulmonary function. For example, in cross-sectional studies in the general 
population, markers of systemic inflammation correlate with lower levels of pulmonary 
function.6970 Yet, conflicting results have been reported from longitudinal population- 
based studies. One group found a relation between C-reactive protein (CRP) and 
the COPD endpoint,71 in contrast to others investigators.70 Finally, COPD patients 
with enhanced systemic inflammatory biomarkers show a faster decline in FEV1.72 
Previous research and the results from studies in chapter 6 demonstrate that moderate 
intense exercise aggravates systemic inflammation in muscle-wasted COPD patients. 
As 40W is comparable to ADL, these results imply that repeated events of enhanced 
inflammation will occur in patients with COPD. This could be compared with other 
repetitive events of enhanced inflammation, like exacerbations, which lead to greater 
levels of systemic inflammation and a faster decline in lung function, more muscle- 
wasting and the occurrence of other comorbidities.11,72 Considering the systemic effects 
of inflammation, as described above, these data might point to an adverse effect of 
exercise in patients with COPD. Furthermore, these data underscore the necessity for 
adequate anti-inflammatory treatments in COPD. Future studies should therefore 
address the efficacy of pharmacological agents with anti-inflammatory properties,
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like statins (chapter 7), N-acetylcysteine,73 phosphodiesterase-4 inhibitors,74 TNF- 
alpha inhibitors,75 and recombinant interleukin-1 receptor antagonists7677 to treat 
systemic inflammation and its consequences in COPD. The same is true for nutritional 
interventions, like anti-oxidants.78 Finally, since inflammatory mediators may arise 
from respiratory muscles,79 the effect of alleviating respiratory muscles, for example by 
Heliox,80 on exercise-induced inflammation could be subject of future research.
The main findings of this thesis are in agreement with the notion that a single 
measurement of FEV1 incompletely represents the complex clinical consequences of 
COPD.1 Therefore, composite outcomes, incorporating extrapulmonary effects, like 
body mass index (B), degree of airflow obstruction (O), dyspnea (D), exercise capacity 
(E) (BODE) have been proposed to better describe disease severity in patients with 
COPD.81 Indeed, BODE predicts mortality better than the traditional FEV1.81 A simplified 
index for use in primary care settings, the age (A), dyspnea (D), airflow obstruction (O) 
(ADO) index, has been developed and showed similar predicting capacities as the BODE 
index.82 Also, it has been proposed to add the term chronic systemic inflammatory 
syndrome to the diagnosis of COPD.68 This syndrome is defined as fulfilling three of the 
following properties: age >40 years, smoking >10 pack years, symptoms and abnormal 
lung function compatible with COPD, chronic heart failure, metabolic syndrome, and 
increased CRP. Whatever the optimal naming may be, it is evident that solely FEV1 is 
unsatisfactory to describe the different phenotypes of COPD. A recently started large 
study investigating systemic biomarkers for defining COPD subtypes and the effect 
of biomarkers on disease progression83 might contribute to a more comprehensive 
description, and ultimately treatment, of patients with COPD.
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SAMENVATTING EN ALGEMENE DISCUSSIE
SAMENVATTING
Chronische obstructieve longziekte (COPD) wordt gekenmerkt door een progressieve 
beperking van de expiratoire flow.1 Ook is COPD geassocieerd met een abnormale 
ontstekingsreactie van de longen op schadelijke deeltjes of gassen en heeft COPD 
systemische consequences.1 In dit proefschrift hebben we geprobeerd om klinisch 
belangrijke gevolgen van deze twee aspecten van COPD te onderzoeken. Ten eerste 
onderzochten we de gevolgen van flowbeperking op operationele longvolumes tijdens 
inspanning. Ten tweede hebben we systemische gevolgen van COPD, zoals systemische 
inflammatie en cardiovasculaire comorbiditeit, onderzocht en samengevat.
Operationele longvolum es b ij COPD
Operationele longvolumes, zoals dynamische hyperinflatie (DH) en inspiratoir reserve 
volume (IRV), worden doorgaans afgeleid uit herhaalde metingen van de inspiratoire 
capaciteit (IC).2 Het doel van hoofdstuk 2 was om de validiteit van Oxycon Mobile, een 
draagbaar en draadloos instrument voor het meten van cardiopulmonale parameters, 
te bepalen betreffende het meten van de IC in rust en tijdens steady-state inspanning.
Oxycon Pro (de vaste versie van dit apparaat) werd beschouwd als de gouden 
standaard. Het verschil in IC gemeten door beide apparaten was in 95% van de gevallen 
maximaal ±10% zowel in rust als tijdens inspanning, wat in overeenstemming is met 
de aanbevolen inter-instrument reproduceerbaarheid.3 We concludeerden dat Oxycon 
Mobile en Oxycon Pro kunnen worden uitgewisseld voor het meten van IC's en dus van 
operationele longvolumes. De Oxycon Mobile werd gebruikt om DH en IRV te bepalen 
tijdens zelfgekozen dyspneu-veroorzakende activiteiten van het dagelijks leven (ADL) 
bij patiënten thuis, in hoo fds tuk  3. Om beter inzicht te krijgen in de oorzaken van 
dyspneu en inspanningsbeperking in het dagelijks leven, werden DH en IRV vergeleken 
bij COPD patiënten met verschillende ernst van de ziekte, namelijk Global initiative for 
chronic Obstructive Lung Disease (GOLD) stadium II-IV. ADL varieerden van stofzuigen 
en tassen dragen to t de afwas doen en wandelen. Er werd geen significant verschil in 
DH gevonden tussen de GOLD categorieën aan het eind van ADL. Op isotime (gelijke 
tijd; 2min) was er een tendens voor een toenemende mate van DH bij toenemend GOLD 
stadium, maar een afname bij GOLD IV patiënten. Dit was in overeenstemming met 
onze hypothese dat DH toeneemt bij toenemende luchtwegobstructie, maar dat het 
effect van deze flowbeperking wordt beperkt door het effect van volumebeperking in 
de patiënten met de meest ernstige COPD. IRV aan het eind van ADL was niet significant 
verschillend, maar op isotime was het significant kleiner in de meest ernstige groepen.
Alleen GOLD IV patiënten bereikten de dyspneu limiet (IRV~0,5L).4 Hoewel GOLD II en
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III patiënten de neiging hadden om meer DH tijdens ADL te ontwikkelen, scoorden ze 
minder dyspneu dan GOLD IV patiënten. GOLD II en III patiënten bereikten de dyspneu 
limiet niet, omdat ze minder statische hyperinflatie hadden. Dit ondersteunt het idee 
dat een beperkt IRV een belangrijkere determinant voor dyspneu is dan DH. Beperking 
van de activiteit in de meest ernstige groep was waarschijnlijk een combinatie van het 
bereiken van de dyspneu limiet en minimale ademhalingsreserve (<11L en/of 15% van 
de maximale vrijwillige ventilatie, dat wordt geschat door 37,5xgeforceerd expiratoir 
1-secondevolume (FEV1)).5 We concludeerden dat DH onafhankelijk van de ernst van de 
ziekte ontstaat tijdens dagelijkse bezigheden. Verder concludeerden we dat een laag 
IRV, welke wordt bepaald door statische plus dynamische hyperinflatie, belangrijker is 
voor dyspneu en inspanningsbeperking dan DH.
In tegenstelling to t wat meestal wordt getest in laboratoriumsituaties (fietsen en lopen), 
is armarbeid een belangrijk onderdeel van ADL. Er wordt meer dyspneu gemeld tijdens 
inspanning met de armen dan tijdens inspanning met de benen.6 Aangezien DH een 
belangrijke bijdrage levert aan dyspneu,4 werd in de studie beschreven in hoofdstuk 
4 de hoeveelheid DH tussen steady-state inspanning met armen en benen (ergometrie) 
vergeleken. Om het effect van de hoeveelheid ventilatie op DH uit te sluiten, werd 
DH gemeten tijdens gelijke ventilatie (isoventilatie). De hypothese was dat DH groter 
is tijdens armergometrie, vooral als gevolg van een grotere afhankelijkheid van de 
ademfrequentie om de ventilatie te verhogen. Het gebruik van thoracale spieren 
voor armpositionering en houding kan leiden to t een stijvere thorax, waardoor het 
moeilijker is om het teugvolume te vergroten. Hierdoor zal de ademfrequentie hoger 
moeten worden om de ventilatie te verhogen. In tegenstelling to t onze hypothese was 
het niveau van DH niet significant verschillend, ondanks een hogere ademfrequentie 
tijdens inspanning met de armen dan tijdens inspanning met de benen. Steady-state 
IRV was significant groter tijdens armergometrie als gevolg van kleinere teugvolumes. 
Tijdens beide soorten inspanning werd de kritische grens van ~0,5L voor het IRV niet 
bereikt. In overeenstemming met deze bevindingen vonden we niet meer dyspneu 
tijdens arm inspanning op isoventilatie. Uit deze studie concludeerden we dat DH gelijk 
is tijdens inspanning met armen en benen op isoventilatie bij patiënten met COPD, 
ondanks een hogere ademfrequentie en daardoor een kortere expiratietijd tijdens 
arm inspanning. Het kan echter zijn dat het verschil in frequentie te klein was om 
effect te hebben op DH, of dat kleine verschillen in DH niet werden gedetecteerd. 
Eerdere studies tonen aan dat veranderingen in operationele longvolumes 
betere voorspellers zijn van patiëntgeoriënteerde uitkomsten, zoals dyspneu, dan 
FEV1.78 In tegenstelling to t de daling van de FEV1, is het onbekend hoe DH zich 
ontwikkelt tijdens het ziekteverloop. Daarom was het doel van hoofdstuk 5 om 
DH te onderzoeken tijdens twee jaar follow-up bij patiënten met COPD. DH werd 
geïnduceerd door metronoom gestuurde hyperventilatie (MPH), een eenvoudig 
surrogaat voor inspanning.9 Bij patiënten met milde to t ernstige COPD vonden we
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een toename in DH van 0,23L gedurende twee jaar follow-up, zonder een verandering 
in de FEV1. Rokers lieten gedurende twee jaar een snellere daling van FEV1 en een 
grotere toename van DH zien dan niet-rokers, terwijl de verandering in statische 
hyperinflatie vergelijkbaar was. Deze resultaten suggereren dat DH een gevoelige 
maat is om de gevolgen van veranderingen in de luchtwegobstructie op te sporen.
Systemische effecten b ij COPD
COPD is geassocieerd met een laaggradige systemische ontsteking,10 die is gerelateerd 
aan de ontwikkeling van systemische comorbiditeiten, zoals hart- en vaatziekten en 
spiermassaverlies.11-15 Ook leidt (submaximale) inspanning to t een ontstekingsreactie 
bij COPD patiënten (met spiermassaverlies).1617 Het doel van hoo fds tuk  6 was om te 
onderzoeken of niet-invasieve beademing (NIV) de systemische inflammatoire respons 
op submaximale inspanning vermindert ten opzichte van controle inspanning. NIV leidt 
over het algemeen to t grotere inspanningstolerantie en minder dyspneu18 door het 
ontlasten van de ademhalingsspieren.19,20 Onze hypothese was dat de inflammatoire 
respons op inspanning onderdrukt zou worden door NIV. NIV verminderde de IL-6 
respons op submaximale inspanning bij COPD patiënten met spiermassaverlies. 
Hoewel de IL-6 respons geremd werd, werd er geen complete onderdrukking van 
de inflammatoire respons waargenomen. Aangezien NIV de ademhalingsspieren 
ontlast, suggereren deze data dat de ademhalingsspieren betrokken zijn bij het 
inspanningsgerelateerde vrijkomen van IL-6. IL-6 speelt een belangrijke rol in de 
ontwikkeling van comorbiditeiten bij COPD21 en ook in de normale fysiologische respons 
op inspanning.22 Daarom moet rekening gehouden worden met deze resultaten als 
NIV tijdens inspanning wordt toegepast bij onderzoek of revalidatie.
Andere interventies in het kader van het beïnvloeden van systemische inflammatie 
zijn statinen. Voornamelijk retrospectieve studies tonen positieve effecten van 
statinen bij COPD, die werden samengevat in hoo fdstuk 7. Statinen verminderen 
veilig de cardiovasculaire morbiditeit en mortaliteit bij patiënten met een verhoogd 
cholesterol in het kader van zowel primaire als secundaire preventie van coronaire 
hartziekten.23,24 Naast cholesterolverlagende effecten zijn zogenaamde pleiotrope of 
cholesterolonafhankelijke effecten gesuggereerd. Veelbelovende effecten van statinen 
bij COPD zijn beschreven op de ontwikkeling en progressie van COPD, morbiditeit 
en mortaliteit. De beschreven studies moeten echter als hypothesevormend worden 
beschouwd. Om daadwerkelijk aan te tonen dat statinen effect hebben bij COPD 
patiënten moeten prospectieve gerandomiseerde trials uitgevoerd worden met klinisch 
relevante eindpunten zoals longfunctie, exacerbatiefrequentie, lichaamssamenstelling, 
spierkracht en inspanningstolerantie.
Hart- en vaatziekten en hartfalen (HF) zijn voorbeelden van comorbiditeiten bij COPD. 
In hoofdstuk 8 beschrijven we de prevalentie van gecombineerd COPD en HF. Het
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vaststellen van de prevalentie van COPD samen met HF is complex om verschillende 
redenen. Ten eerste zijn er overlappende risicofactoren, klachten en symptomen die 
HF diagnostiek bij COPD bemoeilijken en vice versa. Ook neemt het stellen van de 
diagnose van beide ziekten relatief veel tijd in beslag, waardoor diagnoses bij ontslag 
uit het ziekenhuis en/of gegevens over voorgeschreven medicijnen vaak gebruikt 
worden om de gecombineerde prevalentie vast te stellen. Ten slotte zijn de definities 
van beide ziektebeelden in de loop van de tijd veranderd. De prevalentie van HF bij 
COPD werd onderzocht volgens de huidige definities en bleek 21%.25 COPD bij HF 
patiënten lijkt echter niet zo grondig onderzocht en prevalentie op basis van databases 
varieert van 7 to t 51%.26 Linker ventrikel systolische disfunctie lijkt geen belangrijke 
rol te spelen bij COPD patiënten zonder hart- en vaatziekten, in tegenstelling to t 
diastolische linker ventrikel disfunctie.27 Diastolische linker ventrikel disfunctie 
wordt verondersteld te worden gemedieerd door verhoogde pulmonale vasculaire 
weerstand en daardoor verplaatsing van het septum naar links, ook wel ventriculaire 
'interdependence' genoemd.2829 Stijging van de pulmonale vasculaire weerstand 
kan optreden als gevolg van verschillende mechanismen, waaronder het verlies van 
pulmonale vasculaire capaciteit als gevolg van destructie van parenchym, hypoxische 
pulmonale arteriële vasoconstrictie en hyperinflatie.30 31 In niet-geselecteerde (hart- en 
vaatziekten niet als exclusiecriteria) patiënten met COPD zouden hart- en vaatziekten 
een bijkomend mechanisme kunnen zijn voor de verhoogde gelijktijdige prevalentie 
van (systolische en diastolische) linker ventrikel disfunctie/HF.32 Toekomstige studies 
zouden zich moeten richten op een optimale diagnose en behandeling bij patiënten 
met gelijktijdig COPD en HF.
ALGEMENE DISCUSSIE 
O perationele longvolum es b ij COPD
De gegevens uit het eerste deel van dit proefschrift geven meer inzicht in de 
ontwikkeling van DH en een afgenomen IRV. Theoretisch is het voorkomen en de 
hoeveelheid van DH afhankelijk van: (1) de ernst van de expiratoire flowbeperking, (2) 
de hoeveelheid ventilatie, (3) het ademhalingspatroon, en (4) de hoeveelheid statische 
hyperinflatie.
In tegenstelling to t d it model, toonde de studie beschreven in hoofdstuk 3 geen verschil 
in de hoeveelheid DH tussen patiënten met verschillende mate van luchtwegobstructie. 
Deze waarneming werd bevestigd in een follow-up studie (hoofdstuk 5), die, alleen 
in de rokers subgroep, een zwakke correlatie tussen FEV1 en DH liet zien. Dit verschil 
kan worden verklaard door het fe it dat de FEV1 niet de totale luchtwegobstructie 
vertegenwoordigt, omdat obstructie in de kleinere luchtwegen niet weerspiegeld 
wordt in FEV1. Daarom zou het interessant zijn om te bestuderen of DH correleert met
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aanvullende parameters voor luchtwegobstructie die de totale luchtwegobstructie 
beter omschrijven, zoals maten voor perifere obstructie, de negatieve expiratoire druk 
techniek of geforceerde oscillatie techniek.33 34 Zeer recent is er een nieuwe methode 
ontwikkeld om flowbeperking te bepalen tijdens inspanning door het kwantificeren 
van de concaviteit van de spontane expiratoire flow-volume curve, maar deze methode 
moet eerst worden gevalideerd.35
COPD patiënten verhogen hun ventilatie tijdens inspanning vooral door een 
toename van de ademfrequentie, waardoor de expiratietijd afneemt. Omdat er een 
flowbeperking bestaat bij COPD, leidt deze kortere expiratietijd to t DH. We hebben 
niet het effect van verschillende niveaus van ventilatie op DH onderzocht. Echter, in 
hoofdstuk 3 vonden we dat de ventilatie verschillend was tussen de GOLD categorieën, 
en daarom hebben we de snelheid van ontstaan van DH (verandering in IC per 
verandering in ventilatie) achteraf bepaald (gegevens niet getoond). Er werden geen 
verschillen in deze ratio gevonden tussen de GOLD stadia aan het eind van ADL en op 
isotime. Echter, dit soort inspanning is niet geschikt voor onderzoek naar het effect 
van ventilatie op DH. Voor een adequate bepaling van dit effect, zouden herhaalde 
IC metingen tijdens een gestandaardiseerde maximale inspanningstest of tijdens een 
inspanningstest met verschillende steady-state ventilatie niveaus nodig zijn.
Een eerdere studie vergeleek vier fietstesten met variërende constante belasting (op 
65, 75, 85 en 95% van de maximale belasting) en vond dat hogere ademfrequenties 
en kleinere teugvolumes geassocieerd waren met hogere niveaus van DH.36 Andere 
auteurs rapporteerden hogere ademfrequenties en een grotere mate van DH bij 
armtesten met toenemende constante belasting (50, 65, 80% van de maximale 
belasting), waarbij teugvolumes niet genoemd werden.37 Het kan zijn dat de relatie 
tussen ventilatie en DH alleen wordt bepaald door de toename van de ademfrequentie 
en niet door het teugvolume, wat onderwerp van verder onderzoek zou kunnen zijn. 
In hoofdstuk 4, waarbij op isoventilatie arm en been inspanning werd vergeleken, kon 
het effect van de ademfrequentie op de hoeveelheid DH niet worden bevestigd, wat 
verklaard zou kunnen worden door het kleine verschil in frequentie.
Ten slotte is de hoeveelheid DH afhankelijk van het niveau van statische hyperinflatie.38 
In overeenstemming met deze bevinding lieten de resultaten van de studies in de 
hoofdstukken 3-5 zien dat patiënten met hogere niveaus van statische hyperinflatie 
minder DH ontwikkelen. Dit zou verklaard kunnen worden door het hebben van 
minder beschikbare ruimte om verder te hyperinfleren. DH bij deze patiënten leidt 
dan snel to t een IRV kleiner dan 0,5L, ofwel de dyspneu limiet, wat het belang van het 
IRV benadrukt.
Concluderend is het moeilijk specifieke groepen die gevoelig zijn voor en activiteiten 
die leiden to t DH te definiëren, aangezien er meerdere factoren bijdragen aan DH. 
Klinisch relevante DH wordt momenteel gedefinieerd als een daling van de rust IC van 
0,5L na bronchodilatatie, of van 0,3L vóór bronchodilatatie.4 Deze waarden leiden tot
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een sterke toename in dyspneu, evenals een gemeenschappelijke waarde van ~0,5L 
voor IRV.4 Bronchodilatatie resulteert in een grotere rust IC4 en dus minder statische 
hyperinflatie. Er van uitgaande dat de totale longcapaciteit (TLC) stabiel blijft, wordt 
DH na bronchodilatatie beter getolereerd, en b lijft de tolerantie van IRV gelijk. Anderen 
beschouwen een daling van de IC van meer dan 150ml of 10% als DH.39 Verder worden 
ratio's, bijvoorbeeld IC/TLC, gebruikt om DH uit te drukken.2 39 Echter, in tegenstelling 
to t een referentiewaarde van IC/TLC in rust van 0,25,40'42 is er geen referentiewaarde 
bekend voor relevante DH uitgedrukt als IC/TLC tijdens inspanning. Ook zou het beter 
kunnen zijn om IRV uit te drukken als een percentage daling tijdens inspanning of als 
een percentage van TLC, maar hierover zijn geen gegevens beschikbaar. Toekomstig 
onderzoek zou kunnen worden gericht op het bepalen van de beste methode om 
klinisch relevante DH en minimale IRV te beschrijven.
Dit proefschrift toont aan dat DH en IRV gerelateerd zijn aan dyspneu en 
inspanningsintolerantie, zelfs tijdens ADL. Eerdere studies hebben aangetoond 
dat DH na een maximale fietstest de beste voorspeller is van afgenomen fysieke 
activiteit,43 wat op zijn beurt gerelateerd is aan verminderde kwaliteit van leven 
bij COPD.44 Echter, inspanningsintolerantie bij COPD is niet alleen afhankelijk van 
operationele longvolumes. Andere factoren, zoals het bereiken van de minimale 
ademhalingsreserve, hypercapnie, hypoxie, perifere spierdisfunctie en concurrentie 
tussen ademhalingsspieren en spieren van het bewegingsapparaat, spelen een rol 
in een complex samenspel.54546 Ook niet-fysiologische aspecten, zoals angst, kunnen 
bijdragen aan inspanningsintolerantie.47 In mechanistische studies met betrekking to t 
inspanningsbeperking moet ook rekening gehouden worden met niet-fysiologische 
effecten.
Er zijn verschillende interventies onderzocht om inspanningsprestaties te verbeteren. 
Over het algemeen hebben bronchusverwijders geen effect op de hoeveelheid 
DH,94849 maar verbeteren ze statische hyperinflatie en inspanningstolerantie wel.450 
Het is ook aangetoond dat luchtwegverwijders de dynamiek van zuurstoftransport 
naar en gebruik van zuurstof door de spieren verbeteren.51 Longrevalidatie is een 
andere methode om dyspneu te verminderen en inspanningsvermogen en kwaliteit 
van leven te verbeteren.52 Deze multidisciplinaire interventie is gericht op fysieke, 
psychische en sociale aspecten van de ziekte. Het is aangetoond dat er minder DH 
optreedt na revalidatie dan ervoor bij gelijke belasting.53 Verder is aangetoond dat 
aanvullende strategieën zoals ventilatie-feedback resulteren in minder DH.54 Van 
voedingssuppletie, meervoudig onverzadigde vetzuren en anabole steroïden in 
aanvulling op een revalidatieprogramma is gebleken dat de inspanningscapaciteit 
verbetert ten opzichte van revalidatie alleen,55-57 maar het effect op DH werd niet 
beoordeeld. Heliox (Helium-zuurstof mengsel, een gasmengsel met lage dichtheid, 
waardoor de luchtwegweerstand afneemt en daardoor de flow  en ventilatie 
toenemen) en zuurstof (verlaagt de ventilatoire vraag) resulteerden in een verbeterde
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inspanningscapaciteit en minder DH.58’61 In geselecteerde groepen patiënten leidde 
longvolume reductie chirurgie to t een verhoogde inspanningstolerantie en minder 
DH.62 Andere interventies die de inspanningstolerantie uiteindelijk zouden kunnen 
verbeteren zijn farmacologische en voedingsinterventies, die zullen worden besproken 
in de volgende paragraaf.
Systemische effecten b ij COPD
De gegevens uit het tweede deel van dit proefschrift hebben betrekking op systemische 
effecten bij COPD. COPD is een complexe ziekte met meer dan alleen een expiratoire 
flowbeperking. Naast longproblemen kan disfunctie van andere organen optreden 
tijdens de progressie van COPD. Verschillende studies hebben bijvoorbeeld aangetoond 
dat HF een veel voorkomende comorbiditeit bij patiënten met COPD is, zoals besproken 
in hoofdstuk 8. Echter, de pathofysiologische mechanismen die ten grondslag liggen 
aan de co-existentie van deze twee ziekten zijn op d it moment onduidelijk. Interessant is 
dat de belangrijkste determinant van het eerste deel van d it proefschrift, hyperinflatie, 
kan bijdragen aan de ontwikkeling van HF bij COPD. Hyperinflatie is geassocieerd met 
een lagere zuurstof pulse, een maat voor slagvolume, bij patiënten met COPD.42 Er 
zijn verschillende mechanismen voor dit verschijnsel gesuggereerd. Er is geopperd 
dat toename van de intracardiale druk veroorzaakt door hyperinflatie de veneuze 
return en het slagvolume vermindert.31 42 63 Anderen suggereerden dat de veneuze 
return (preload) juist toeneemt door grote negatieve veranderingen in intrathoracale 
druk om de inspiratoire threshold load (ten gevolge van DH) te overwinnen, en door 
overmatig gebruik van de abdominale (expiratie) spieren (hoewel dit overmatig 
gebruik ook gezien kan worden als een Valsalva manoeuvre wat leidt to t verminderde 
veneuze return).6465 Verder treedt er een verhoogde pulmonale vaatweerstand en 
afterload voor de rechter ventrikel op als gevolg van toegenomen longvolume (en 
vernietiging van longparenchym en hypoxie).64 Zowel de toegenomen preload, wat 
leidt to t verplaatsing van het septum naar links, als de toegenomen afterload voor 
de rechter ventrikel resulteren in een kleiner slagvolume van de linker ventrikel.64 Het 
gemeenschappelijke gevolg van de voorgestelde mechanismen is een afname van het 
hartminuutvolume als gevolg van (dynamische) hyperinflatie.42 6466 
Systemische manifestaties, zoals systemische inflammatie, hypoxie, verhoogde 
sympathische activatie, vasculaire disfunctie, degradatie van bindweefsel en versnelde 
veroudering, zullen waarschijnlijk bijdragen aan het frequent samengaan van COPD 
en hart- en vaatziekten.32 67 Hoewel de betrokkenheid van systemische inflammatie 
het meest uitgebreid onderzocht is, kunnen er geen definitieve conclusies getrokken 
worden. Allereerst is de oorsprong van systemische inflammatie onduidelijk en 
waarschijnlijk multifactorieel bepaald.11 Er is bijvoorbeeld gesuggereerd dat 
systemische inflammatie een spill-over is van pulmonale ontstekingsmediatoren
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in de circulatie. Aan de andere kant zou pulmonale inflammatie simpelweg deel 
kunnen zijn van een systemische inflammatoire toestand met betrokkenheid van 
meerdere organen.68 Daarnaast kan systemische inflammatie het gevolg zijn van 
enige comorbiditeit, met latere effecten op de long.12,14 Tot slot is onderscheid tussen 
een systemische manifestatie van COPD en 'onafhankelijke' comorbiditeit moeilijk.12 
Toekomstig onderzoek moet de complexe relatie tussen COPD, comorbiditeit, en 
systemische inflammatie ophelderen.
Ongeacht de oorsprong ervan, wordt gedacht dat laaggradige systemische ontsteking de 
longfunctie aantast. Bijvoorbeeld, in cross-sectionele studies in de algemene bevolking 
correleren markers van systemische inflammatie met slechtere longfunctie.69,70 Echter, 
er zijn tegenstrijdige resultaten beschreven van longitudinale studies in de algemene 
bevolking. Eén groep vond een relatie tussen C-reactief proteïne (CRP) en het ontstaan 
van COPD,71 in tegenstelling to t andere onderzoekers.70 Tot slot laten COPD patiënten 
met verhoogde systemische inflammatoire biomarkers een snellere daling van FEV1 
zien.72
Eerder onderzoek en de resultaten van de studie in hoofdstuk 6 tonen aan dat er 
tijdens submaximale inspanning een systemische inflammatoire respons optreedt bij 
COPD patiënten met spiermassaverlies. Aangezien een belasting van 40W vergelijkbaar 
is met ADL, impliceren deze resultaten dat bij patiënten met COPD deze inflammatoire 
respons herhaaldelijk optreedt. Dit kan worden vergeleken met andere herhaalde 
gebeurtenissen met toegenomen inflammatie, zoals exacerbaties, die leiden to t 
hogere niveaus van systemische inflammatie en een snellere daling van de longfunctie, 
meer spiermassaverlies en het optreden van andere comorbiditeiten.1172 Gezien de 
systemische effecten van inflammatie, zoals hierboven beschreven, zouden deze 
gegevens kunnen wijzen op een negatief effect van lichaamsbeweging bij patiënten 
met COPD. Verder onderstrepen deze gegevens de noodzaak van een adequate 
anti-inflammatoire behandeling bij COPD. Toekomstige studies moeten daarom 
de werkzaamheid aantonen van farmacologische stoffen met anti-inflammatoire 
eigenschappen, zoals statinen (hoofdstuk 7), N-acetylcysteine,73 fosfodiësterase-4 
remmers,74 TNF-alfa remmers,75 en recombinant IL-1 receptor antagonisten7677 om 
systemische inflammatie en de gevolgen daarvan bij COPD te behandelen. Hetzelfde 
geldt voor voedingsinterventies, zoals anti-oxidanten en vitamines.78 Tot slot, 
aangezien de ademhalingsspieren een bron van ontstekingsmediatoren kunnen 
zijn,79 zou het effect van het ontlasten van de ademhalingsspieren, bijvoorbeeld 
door Heliox,80 op inspanninggeïnduceerde inflammatie onderwerp kunnen zijn van 
toekomstig onderzoek.
De belangrijkste bevindingen van dit proefschrift zijn in overeenstemming met 
de gedachte dat een enkele meting van FEV1 onvolledig de complexe klinische 
consequenties van COPD vertegenwoordigt.1 Daarom zijn samengestelde
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uitkomsten, met daarin extrapulmonale effecten, zoals body mass index (B), mate 
van luchtwegobstructie (O), kortademigheid (D) en inspanningscapaciteit (E) (BODE), 
voorgesteld om de ernst van COPD beter te beschrijven.81 Inderdaad, BODE voorspelt 
de mortaliteit beter dan de traditionele FEV1.81 Een vereenvoudigde index, leeftijd 
(A), kortademigheid (D) en luchtwegobstructie (O) (ADO) index, is ontwikkeld voor 
gebruik in de eerste lijn en heeft een soortgelijke voorspellende waarde als de BODE 
index.82 Ook is gesuggereerd om de term chronisch systemisch inflammatoir syndroom 
toe te voegen aan de diagnose COPD.68 Dit syndroom wordt gedefinieerd als het 
hebben van drie of meer van de volgende eigenschappen: leeftijd >40 jaar, roken >10 
pakjaren, klachten en abnormale longfunctie passend bij COPD, chronisch hartfalen, 
metabool syndroom en verhoogde CRP. Wat de optimale definitie ook moge zijn, het 
is duidelijk dat FEV1 alleen onvoldoende is om de verschillende fenotypen van COPD 
te beschrijven. Een onlangs gestart groot onderzoek naar systemische biomarkers voor 
het definiëren van COPD subtypen en het effect van biomarkers op progressie van de 
ziekte83 zou kunnen bijdragen aan een meer omvattende beschrijving en uiteindelijk 
behandeling van patiënten met COPD.
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